Phenyl-substituted imidazopyridines

ABSTRACT

The invention features pharmaceutically-active imidazopyridines and derivatives that are substituted with phenyl, methods of making them, and methods of using them.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional Application Ser.No. 60/194,071, filed on Mar. 31, 2000, our Docket Number ORT-1158 andU.S. Provisional Application Ser. No. 60/______, filed on Feb. 28, 2001,our Docket Number ORT-1362.

FIELD OF THE INVENTION

The invention relates to pharmaceutically-active fused heterobicycliccompounds and methods of using them to treat or prevent disorders andconditions, such as those mediated by the histamine H₃ receptor.

BACKGROUND

The histamine H₃ receptor is located as a presynaptic autoreceptor inthe central nervous system and as a presynaptic heteroreceptor onserotonergic, noradrenergic, dopaminergic, and cholinergic neurons. Thehistamine H₃ receptor is also located peripherally in tissues such asvascular smooth muscle cells.

Proposed uses of histamine H₃ antagonists include the treatment orprevention of dementia, Alzheimer's disease (Panula et al. Abstr.Society Neuroscience, 1995, 21:1977), epilepsy (Yokoyama et al. Eur. J.Pharmacol., 1993, 234:129), sleep/wake disorders (Lin et al., Br. Res.,1990, 523, 325; Monti et al., Eur. J. Pharmacol., 1991, 205, 283)including narcolepsy, insomnia, and jet lag, eating disorders (Machidoriet al. Brain Research, 1992, 590:180), motion sickness, vertigo,attention deficit hyperactivity disorder, learning and memory disorders(Barnes et al. Abstr. Society Neuroscience, 1993, 19:1813),schizophrenia (Schlicker et al. Naunyn Schmiedeberg's Arch. Pharmacol.,1996, 353:325), and sequelae associated with post-ischemic reperfusionand hypertension (Imamura et al., J. Pharmacol. Expt. Ther., 1994, 271,1259). H₃ antagonists are also useful to treat or prevent neurogenicinflammation such as migraine (McLeod et al., Abstr. SocietyNeuroscience, 1996, 22, 2010), asthma (Ichinose et al., Eur. JPharmacol., 989, 174, 49), obesity, allergic rhinitis, substance abuse,bipolar disorders, manic disorders, and depression. Histamine H₃antagonists alone or in combination with a histamine H₁ antagonist arebelieved to be useful in the treatment of upper airway allergic responseor allergic rhinitis (see, e.g., U.S. Pat. Nos. 5,217,986, 5,352,707,and 5,869,479).

As noted, the prior art related to histamine H₃ ligands wascomprehensively reviewed recently (“The Histamine H ₃ Receptor-A Targetfor New Drugs”, Leurs, R., and Timmerman, H., (Editors), Elsevier,1998). Within this reference the medicinal chemistry of histamine H₃agonists and antagonists was reviewed (see Krause et al. and Phillips etal., respectively). Thus the importance of an imidazole moietycontaining only a single substitution in the 4 position was notedtogether with the deleterious effects of additional substitution onactivity. Particularly methylation of the imidazole ring at any of theremaining unsubstituted positions was reported to strongly decreaseactivity.

More recently several publications have described histamine H₃ ligandsthat do not contain an imidazole moiety. Examples include Ganellin et alArch. Pharm. (Weinheim, Ger.) 1998, 331, 395; Walczynski et al Arch.Pharm. (Weinheim, Ger.) 1999, 332, 389; Walczynski et al Farmaco 1999,684; Linney et al J. Med. Chem. 2000, 2362; U.S. Pat. No. 5,352,707; PCTApplication WO99/42458, published Aug. 26, 1999; and European PatentApplication 0978512, published on Feb. 9, 2000.

SUMMARY OF THE INVENTION

The invention features phenyl-substituted imidazopyridine compounds,methods of making them, and methods of using them. One aspect of theinvention provides compounds of the following formula (I)(A):

wherein both dashed lines are present to form carbon-carbon doublebonds; or both dashed lines are absent;

-   -   R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl;    -   each of R₅, R₆, R₇ and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆        alkoxy, halo, or amino;    -   one of R_(a), R_(b), R_(c), R_(d), and R_(e) is —WYZ and the        others are independently selected from H, C₁₋₆ alkyl, C₁₋₆        alkoxy, halo, and amino;    -   W is R₉, O—R₉, NR₁₀, —(CO)(O)R₉, —N(R₁₀)SO₂—R₉, —O(CO)R₉,        —(CO)NR₁₀, or —N(R₁₀)—CO—R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆        alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ heterocyclic        bivalent radical, and R₁₀ is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆        alkenyl, phenyl, or C₂₋₅ heterocyclic radical;    -   Y is absent, C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, or        bivalent C₁₋₆ alkoxy;    -   Z is C₂₋₈ heterocyclic radical with at least one basic nitrogen        atom in the ring, optionally including in the ring up to 3        additional heteroatoms or moieties independently selected from        O, C═O, N, NH, NG, S, SO, and SO₂, wherein G is R₁₅, COR₁₅,        COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅; or Z is NR₁₁R₁₂ where each of R₁₁        and R₁₂ is independently selected from H, C₁₋₆ alkyl, phenyl,        benzyl, C₃₋₈ cycloalkyl, and C₂₋₅ heterocyclic radical; and R₁₅        is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or        C₄₋₇ cycloalkenyl;    -   provided that where R_(c) is WNR₁₁R₁₂, each of R₁₁ and R₁₂ being        independently selected from C₁₋₆ alkyl, then at least one of the        following is true: R_(b) or R_(d) is alkyl, alkoxy, amino, or        halo; the dashed lines represent one carbon-carbon double bond        or are absent; R_(a) or R_(e) is alkyl, alkoxy, amino, or halo;        or W is —R₉—, —NR₁₀—, —(CO)(O)R₉—, —O(CO)R₉—, —(CO)NHR₉—, or        —N(R₁₀)(CO)R₉—;    -   and further provided that where each of R_(a), R_(b), R_(d), and        R_(e) is H, and W is a straight chain, unsubstituted alkoxy,        then at least one of the following is true: Z is cyclic; the        dashed lines represent one carbon-carbon double bond or are        absent; or R₇ or R₈ is alkyl, alkoxy, halo, or amino;    -   and further provided that where each of R_(a), R_(b), R_(d), and        R_(e) is H, and W is a straight chain, unsubstituted propoxy,        then YZ is not N-piperidyl or N-morpholinyl; and    -   each of the above hydrocarbyl or heterocyclic groups being        optionally substituted with between 1 and 3 substituents        selected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic        radical, phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the        above heterocyclic groups may be attached to the rest of the        molecule by a carbon atom or a heteroatom;    -   or a pharmaceutically acceptable salt, amide, ester, or hydrate        thereof.

According to another aspect of the invention, the disclosed compounds offormula (I)(A) and certain other compounds represented by formula (I)(A)without the proviso that where each of R_(a), R_(b), R_(d), and R_(e) isH, and W is a straight chain, unsubstituted propoxy, then YZ is notN-piperidyl or N-morpholinyl, are useful for the treatment and/orprevention of diseases and conditions mediated by the histamine 3 (H₃)receptor. Examples of these other compounds include2-(4-piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine and2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

A third aspect of the invention features methods of making the disclosedcompounds.

Additional features of the invention are disclosed in the followingdescription and examples, and in the appended claims.

DETAILED DESCRIPTION

The invention features pharmaceutically active phenyl-substitutedimidazopyridines and methods of making and using them. The descriptionis organized as follows:

-   -   A. Terms    -   B. Compounds    -   C. Synthetic Methods    -   D. Uses    -   E. Synthetic Chemical Examples    -   F. Biological Examples    -   G. Other Embodiments    -   H. Claims        A. Terms

The following terms are defined below and by their usage throughout thisdisclosure.

“Alkyl” includes straight chain and branched hydrocarbons with at leastone hydrogen removed to form a radical group. Alkyl groups includemethyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,1-methylpropyl, pentyl, isopentyl, sec-pentyl, hexyl, heptyl, octyl, andso on. Alkyl does not include cycloalkyl.

“Alkenyl” includes straight chain and branched hydrocarbon radicals asabove with at least one carbon-carbon double bond (sp²). Alkenylsinclude ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl),isopropenyl (or 1-methylvinyl), but-1-enyl, but-2-enyl, butadienyls,pentenyls, hexa-2,4-dienyl, and so on. Hydrocarbon radicals having amixture of double bonds and triple bonds, such as 2-penten-4-ynyl, aregrouped as alkynyls herein. Alkenyl does not include cycloalkenyl.

“Alkynyl” include straight chain and branched hydrocarbon radicals asabove with at least one carbon-carbon triple bond (sp). Alkynyls includeethynyl, propynyls, butynyls, and pentynyls. Hydrocarbon radicals havinga mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, aregrouped as alkynyls herein. Alkynyl does not include cycloalkynyl.

“Alkoxy” includes a straight chain or branched alkyl group with aterminal oxygen linking the alkyl group to the rest of the molecule.Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy,pentoxy and so on. “Aminoalkyl”, “thioalkyl”, and “sulfonylalkyl” areanalogous to alkoxy, replacing the terminal oxygen atom of alkoxy with,respectively, NH (or NR), S, and SO₂.

“Aryl” includes phenyl, naphthyl, biphenylyl, and so on.

“Cycloalkyl” includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, cyclooctyl, and so on.

“Cycloalkenyl” includes cyclobutenyl, cyclobutadienyl, cyclopentenyl,cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cyclohexatrienyl(phenyl), cycloheptenyl, and so on. “Cycloalkynyl” includes theanalogous rings with one or more triple bonds.

“Heterocyclic radicals” include aromatic and nonaromatic rings havingcarbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety(SO₂, CO, CONH, COO) in the ring. Unless otherwise indicated, aheterocyclic radical may have a valence connecting it to the rest of themolecule through a carbon atom, such as 3-furyl or 2-imidazolyl, orthrough a heteroatom, such as N-piperidyl or 1-pyrazolyl. Examples ofheterocyclic radicals include thiazoylyl, furyl, pyranyl,isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl,isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl,isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl,pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl,pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl. Forexample, preferred heterocyclic radicals for Z include morpholinyl,piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino,cycloheptylimino,and more preferably, piperidyl.

“halo” includes fluoro, chloro, bromo, and iodo, and preferably fluoroor chloro.

“patient” or “subject” includes mammals such as humans and animals(dogs, cats, horses, rats, rabbits, mice, non-human primates) in need ofobservation, experiment, treatment or prevention in connection with therelevant disease or condition. Preferably, the patient is a human.

“composition” includes a product comprising the specified ingredients inthe specified amounts as well as any product which results directly orindirectly from combinations of the specified ingredients in thespecified amounts.

Concerning the various radicals in this disclosure and in the claims,two general remarks are made. The first remark concerns valency. As withall hydrocarbon radicals, whether saturated, unsaturated or aromatic,and whether or not cyclic, straight chain, or branched, and alsosimilarly with all heterocyclic radicals, each radical includessubstituted radicals of that type and monovalent, bivalent, andmultivalent radicals as indicated by the context of the claims. Thecontext will indicate that the substituent is an alkylene or hydrocarbonradical with at least two hydrogen atoms removed (bivalent) or morehydrogen atoms removed (multivalent). An example of a bivalent radicallinking two parts of the molecule is —CH₂—CH₂—, or W in formula (I)(A)which links Z with the phenyl group Ar and thus, subject to the claims,W can be an alkyl (strictly, alkylene) group (—Ar—CH₂CH₂CH₂-Z), anaminoalkyl group (—Ar—NH—CH₂CH₂CH₂-Z), an alkoxy group(—Ar—O—CH₂CH₂CH₂-Z), an “oxa” (—Ar—O-Z), a covalent bond (—Ar-Z), and soon.

Second, radicals or structure fragments as defined herein are understoodto include substituted radicals or structure fragments. Using “alkyl” asan example, “alkyl” should be understood to include substituted alkylhaving one or more substitutions, such as between 1 and 5, 1 and 3, or 2and 4 substituents. The substituents may be the same (dihydroxy,dimethyl), similar (chlorofluoro), or different (chlorobenzyl- oraminomethyl-substituted). Examples of substituted alkyl includehaloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl,perchloromethyl, 2-bromoethyl, and 3-iodocyclopentyl), hydroxyalkyl,aminoalkyl, nitroalkyl, alkylalkyl, and so on.

Preferred substitutions for Ar include methyl, methoxy,trifluoromethoxy, difluoromethoxy, fluoromethoxy, fluoromethyl,difluoromethyl, perfluoromethyl (trifluoromethyl), 1-fluoroethyl,2-fluoroethyl, ethoxy, fluoroethoxy, fluoro, chloro, and bromo, andparticularly methyl, fluoromethyl, perfluoro, trifluoromethoxy,difluoromethoxy, methoxy, and fluoro.

Examples of other substituted radicals or fragments include1-methyl-2-pyrrolidino, 4-(piperidyl)-piperidyl,[4-(N-benzyl)piperidyl]amino, 4-fluorobenzylamino, beta-hydroxyethoxy,beta-hydroxypropoxy, 2-oxo-pyrrolidino, 4-(1-methyl-4-piperidinyl),4-(5-methyl-thiazoyl), 4-chlorobenzyl, 4-fluorobenzyl, and4-methylbenzyl.

B. Compounds

One aspect of the invention features compounds of formula (I) asdescribed in the Summary section above.

Preferred compounds of formula (I) include those compounds wherein: (a)Z comprises piperidyl, morpholinyl, benzyl amino, phenyl amino,substituted benzyl amino, piperazinyl, pyrrolidyl, or a C₆₋₈cycloalkylimino radical; (b) Z is NR₁₁R₁₂ where each of R₁₁ and R₁₂ isindependently selected from H, C₁₋₄ alkyl, phenyl, and benzyl; (c) W ishydroxy-substituted bivalent C₂₋₄ alkoxy, bivalent C₂₋₄ alkoxy, bivalentC₂₋₄ alkylamino, butenylene, or butynylene; (d) W comprises propoxy,ethoxy, propylamino, or ethylamino; and R₇ or R₈ is methyl; (e) R₇ ismethyl; (f) at least one of R_(a), R_(b), R_(d), and R_(e) is methyl;(g) each of R₅, R₆, R₇ and R₈ is independently H, methyl, ethyl,methoxy, ethoxy, halomethyl, fluoro, or chloro (and preferablyhalomethyl, methyl or fluoro); or wherein one of R_(a), R_(b), R_(c),R_(d), and R_(e) is WZ and the others are independently selected from H,methyl, ethyl, methoxy, ethoxy, halomethyl, fluoro, or chloro (andpreferably halomethyl, methyl or fluoro); or both; (h) the dashed linesare two carbon-carbon double bonds (for example, between C-5 and C-6 andbetween C-7 and C-8 to form an imidazopyridine skeleton); (i) the dashedlines are absent, thereby forming a tetrahydroimidazopyridine skeleton;(j) R_(a) or R_(e) is methyl, fluoro, or methoxy; (k) provided thatwhere each of R_(a), R_(b), R_(d), and R_(e) is H, and W is a straightchain, unsubstituted bivalent alkoxy, then at least two of the followingare true: Z is cyclic; at least one of the dashed lines is absent; or R₇or R₈ is methyl; (I) provided that where R_(c) is WNR₁₁R₁₂, each of R₁₁and R₁₂ being independently selected from C₁₋₆ alkyl, then at least twoof the following are true: R_(b) or R_(d) is methyl, methoxy, ethyl,ethoxy, or halo; at least one of the dashed lines is absent; R_(a) orR_(e) is methyl, methoxy, ethyl, ethoxy, fluoro, or chloro; or W is R₉,—(CO)(O)R_(g), —O(CO)R₉, —(CO)NHR₉, —N(R₁₀)—CO—R₉, or NR₁₀; orcombinations thereof.

Additional preferred compounds include those wherein: (m) R₃is H ormethyl; each of R_(b) and R_(d) is independently H, methyl, or methoxy;each of R₇ and R₈ is independently H, methyl, fluoro, or chloro; each ofR₅ and R₆ is H; each of R_(a) or R_(e) is independently H, methyl,fluoro, or chloro; W is C₂₋₄ alkoxy, C₄ alkylene, C₄ alkynylene, C₄alkenylene, , —N(R₁₀)SO₂—(C₁₋₅ alkyl), —(CO)O—C₂₋₃ alkyl, —(CO)NH—(C₁₋₃alkyl), —NH(CO)(C₁₋₃ alkyl), or NH(C₁₋₆ alkyl); and Z is pyrrolidyl,piperidyl, morpholinyl, piperazinyl, (piperidyl)-piperidyl, or NR₁₁R₁₂where each of R₁₁ and R₁₂ is independently selected from H, C₁₋₅ alkyl,phenyl, benzyl, C₃₋₈ cycloalkyl, and C₂₋₅ heterocyclic radical, but atleast one of R₁₁ and R₁₂ is not H; or taken together, R₁₁ and R₁₂ withthe N to which they are attached form a C₆₋₈ cycloalkylimino radical.

As an alternative to the proviso that “where each of R_(a), R_(b),R_(d), and R_(e) is H, and W is a straight chain, unsubstituted propoxy,then YZ is not N-piperidyl or N-morpholinyl,” the invention alsocontemplates replacing that provision with the proviso that “where YZ isN-piperidyl or N-morpholinyl, and W is a straight chain, unsubstitutedpropoxy, then at least one of the following is true: at least one ofR_(a), R_(b), R_(d), and R_(e) is alkoxy, alkyl, or halo; R₈ is notmethyl or R₇ is not H; or the dashed lines represent one double bond orare absent.”

Examples of more preferred compounds include the following:2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine;(E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine;2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine;2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine;andN,N-Diethyl-N′-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine.

Additional examples of preferred compounds include:2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine;2-(4-Cycloheptylaminopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine;2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine;2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine;2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine;2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;and 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

Preferred compounds include:N,N-Diethyl-N′-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine;7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine;andN,N-Diethyl-N′-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine.Examples of compounds which are preferred in the disclosed methods oftreatment include the above compounds and compounds such as2-(4-piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine and2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

Other examples of compounds, and methods of making them, are provided inthe next section.

C. Synthetic Methods

The invention provides methods of making the disclosed compoundsaccording to traditional organic synthetic methods as well as matrix orcombinatorial synthetic methods. Schemes 1 through 10 describe suggestedsynthetic routes. Using these Schemes, the guidelines below includingU.S. Pat. No. 4,727,145 and Sanfilippo, et al. J. Med. Chem. 188, 31,2221 (1988), both incorporated by reference, and the examples in sectionE, a person of skill in the art may develop analogous or similar methodsfor a given compound. Examples of the described synthetic routes includeSynthetic Examples 1 through 55. Compounds analogous to the targetcompounds of these examples can be, and in many cases have been, madeaccording to analogous routes. The disclosed compounds are useful inbasic research, in diagnostic assays, and as pharmaceutical agents asdescribed in the next section.

It should noted that throughout the Schemes the position of substitutionis indicated by defining substituent Rc in formula I. However it will berecognized by one skilled in the art that the substituent may be locatedat Ra, Rb, Rd or Re and that position Rc is chosen for illustrativepurposes only.

Compounds of formula V, wherein the substituents are as defined informula I, may be prepared according to the process outlined inScheme 1. Specifically a compound of formula II in Step A is treatedwith bromine in a solvent such as ether, chloroform, dichloromethane,carbon tetrachloride or the like, to yield a compound of formula III.The compound of formula III in Step B is reacted with a 2-aminopyridineof formula IV in a solvent such as ethanol, methanol, butanol,iso-propanol, toluene or the like at elevated temperatures, for examplefrom 50° C. up to the boiling point of the selected solvent, preferablyat from 50° C. to 75° C. to give a compound of formula V.

A compound of formula VIII may be prepared from a compound of formula VIas indicated in Scheme 2 using the conditions described for Steps A andB in Scheme 1.

A compound of formula XII may be prepared from a compound of formula IXas shown in Scheme 3 using Steps A and B as described in Scheme 1. InStep C the nitro functionality may be reduced to the corresponding amineto give compounds of formula XII. Reduction may be effected via hydrogengas over a catalyst, for example palladium on carbon, platinum oxide,Raney nickel and the like in a solvent, for example methanol, ethanol orthe like. Reduction may also be effected via transfer hydrogenationtechniques, for example using cyclohexadiene as a source of hydrogen.Reduction may also be effected using zinc or iron in the presence of anacid, for example hydrochloric acid. A preferred method of reduction istransfer hydrogenation using cyclohexadiene in the presence ofpalladium.

A compound of formula XVI may be prepared as shown in Scheme 4. In StepD a compound of formula 11 is reacted with a suitably substitutedcompound of formula X—Y—Cl where Y is defined and X is selected from thegroup consisting of Br, I, mesylate and tosylate such that under thereaction conditions a compound of formula XIII is obtained. Thistransformation is effected in the presence of a base, for examplepotassium carbonate, sodium hydroxide, triethylamine and the like, in asolvent, for example ethanol, methanol, acetone, dichloromethane, DMF,THF and the like. Preferred conditions use potassium carbonate inacetone. The compound of formula XIV may be obtained according to theprocedure of Step A as described for Scheme 1. The compound of formulaXV is obtained upon reacting a compound of formula XIV with a compoundof formula IV according to Step B of Scheme 1. A compound of formula XVIis obtained in Step E by reacting a compound of formula XV with an amineat elevated temperature, preferably neat amine at a temperature from 50°C. to the boiling point of the amine, more preferably at about 80° C. to100° C. Alternatively the compound of formula XV may be treated with anamine in the presence of a base, for example potassium carbonate or thelike in a solvent, for example acetone at elevated temperature, forexample at about 55° C.

Compounds of formula XIX and XXII may be prepared according to theprocedures shown in Scheme 5. Thus in Step F a compound of formula XVIIImay be prepared by reacting a compound of formula XII with a carboxylicacid of formula XVII. The compound of formula XVII may initially beconverted to the corresponding acid chloride or active ester by knownmethods and then reacted with the compound of formula XII in a solventsuch as dichloromethane, THF and the like. A preferred method involvesthe conversion of a compound of formula XVII to the corresponding activeester upon treatment with 1-hydroxybenzotriazole in the presence of acarbodiimide, for example dicyclohexylcarbodiimide or1-ethyl-3-(3′-dimethylaminopropyl)-carbodiimide hydrochloride in thepresence of a base such as triethylamine or N,N-diisopropylethylamine togive a compound of formula XVIII. In Step G the compound of formulaXVIII may be reduced to give a compound of formula XIX. Suitablereducing agents include lithium aluminum hydride, alane, sodiumborohydride in the presence of acid and borane. A preferred method forthe reduction of XVII to XIX is borane-methylsulfide complex in toluene.A compound of formula XXII may be prepared from a compound of formulaXII as shown in Scheme 5. Thus in Step H a compound of formula XII isreacted with a sulfonyl chloride of formula XX in a solvent, for exampleTHF, DMF and the like. A compound of formula XXII is obtained byreacting a compound of formula XXI in Step I with an amine according tothe procedures described for Step E in Scheme 4.

A compound of formula XXIV may be prepared according to the processoutlined in Scheme 6. A compound of formula XV may be reduced in Step Jto give a compound of formula XXIII. This transformation may be effectedusing hydrogenation over a catalyst, for example hydrogen over platinumoxide in a solvent, for example ethanol, methanol or the like, at apressure from 30 to 80 psi. A preferred method uses platinum oxidecatalyst in ethanol at 40 to 50 psi. A compound of formula XXIV may beobtained by reacting a compound of formula XXIII with an amine accordingto the procedures described for Step E in Scheme 4.

Compounds of formula XXVI may be prepared according to Scheme 7 byreacting a compound of formula V in Step K with epichlorohydrin in asolvent, for example methanol, ethanol or the like, in the presence of abase, for example sodium hydroxide or potassium hydroxide or the like. Acompound of formula XXVI may be obtained from a compound of formula XXVaccording to Step L by treating a compound of formula XXV with an amine,ZH, at elevated temperature, for example 80° C. to 140° C., if desiredin the presence of a solvent, for example 2-methoxyethylether,di(ethyleneglycol)ethylether or the like.

Compounds of formula XXVIII may be prepared according to Scheme 8. InStep M a compound of formula VII is reacted with the appropriateterminal alkene, of general formula indicated, in the presence of abase, for example triethylamine or N,N-diisopropylethylamine, in thepresence of triphenylphosphine and a palladium catalyst, for examplepalladium acetate, in a solvent such as DMF, at elevated temperature toafford a compound of formula XXVII. A compound of formula XXVIII may beobtained according to Step N. Thus a compound of formula XXVII may besubjected to hydrogenation over a catalyst, for example platinum oxide,in a solvent such as methanol, ethanol or the like, at elevatedpressure, for example 40 to 70 psi.

Compounds of formula XXX and XXXI may be prepared from compounds offormula VII according to Scheme 9A. In Step O a compound of formula VIIis reacted with a terminal acetylene in the presence of a catalyst, forexample tetrakis(triphenylphosphine)palladium or the like in a solventsuch as acetonitrile or the like, in the presence of copper(I)iodide, togive a compound of formula XXIX. A compound of formula XXIX may beconverted to a compound of formula XXX and/or formula XXXI according toStep P upon hydrogenation over palladium on barium sulfate, nickelacetate with sodium borohydride (P2 nickel), Lindlars catalyst,palladium on carbon or the like in ethanol, methanol or the like. Itwould be recognized that the appropriate choice of reaction conditionswill favor a compound of a particular formula.

Compounds of formula XXXII, XXXIII and XXXIV may be prepared as shown inScheme 9B according to Step Q. Thus the hydroxyl functionality ofcompounds XXX, XXIX and XXXI may be converted into a leaving group, forexample a chloride, bromide, iodide, mesylate, tosylate or the like. Ina preferred embodiment the compounds of formula XXX, XXIX and XXXI areconverted to the corresponding mesylates upon treatment withmethanesulfonyl chloride, in a solvent, for example dichloromethane, THFor the like, in the presence of a base, for example triethylamine,potassium carbonate or the like. The mesylate, or other leaving group,may be displaced under the conditions of Step E, Scheme 4. For exampleupon treatment with an amine, in acetonitrile, in the presence ofpotassium carbonate.

Compounds of formula XXXVIII and XXXIX may be prepared from compounds offormula XXXV. Thus compounds of formula XXXVII may be prepared fromcompounds of formula XXXV using the procedures of Steps A and B ofScheme 1. Compounds of formula XXXVIII may be prepared from compounds offormula XXXVII according to Step R using conventional methods of amidebond formation. For example the carboxyl group of compound XXXVII may beactivated as an active ester, acid chloride, anhydride, mixed anhydride,carbonic mixed anhydride or the like and treated with an aminecontaining group to give a compound of formula XXXVIII. In a preferredmethod a compound of formula XXXVII is treated with carbonyl diimidazolein a solvent such as THF, ether or the like, followed by an aminecomponent. A compound of formula XXXIX may be prepared according to theprocedure of Step S whereupon a compound of formula XXXVII is activatedand then condensed with an alcohol containing moiety to afford acompound of formula XXXIX. In a preferred embodiment a compound offormula XXXVII in dichloromethane is treated withN,N′-dicyclohexylcarbodiimide, in the presence of a base such asN,N-dimethylaminopyridine to give a compound of formula XXXIX.

D. Uses

According to the invention, the disclosed compounds and compositions areuseful for the amelioration of symptoms associated with, the treatmentof, and/or the prevention of, the following conditions and diseases, orsymptoms associated with them: dementia, Alzheimer's disease,narcolepsy, eating disorders, motion sickness, vertigo, attentiondeficit hyperactivity disorder, learning and memory disorders,schizophrenia, mild cognitive impairment, upper airway allergic response(allergic rhinitis), insomnia, jet lag, obesity, asthma, neurogenicinflammation, substance abuse, bipolar disorders, manic disorders, anddepression. The invention also features pharmaceutical compositions,which include, without limitation, one or more of the disclosedcompounds, and a pharmaceutically acceptable carrier or excipient.

1. Dosages

Those skilled in the art will be able to determine, according to knownmethods, the appropriate dosage for a patient, taking into accountfactors such as age, weight, general health, the type of symptomsrequiring treatment, and the use of other medications. An effectiveamount means that amount of pharmaceutical reagent (such as a prodrug,metabolic precursor, or active compound) that elicits the biological ormedical response desired. In general, a therapeutically effective amountwill be between 0.01 and 1000 mg/kg per day, preferably between 0.01 and250 mg/kg body weight, and daily dosages will be between 0.50 and 5000mg for an adult subject of normal weight. Capsules, tablets or otherformulations (such as liquids and film-coated tablets) may be of between0.20 and 100 mg, such as 0.20, 0.50, 1, 2, 3, and 10 mg can beadministered according to the disclosed methods.

2. Formulations

Dosage unit forms include tablets, capsules, pills, powders, granules,aqueous and nonaqueous oral solutions and suspensions, and parenteralsolutions packaged in containers adapted for subdivision into individualdoses. Dosage unit forms can also be adapted for various methods ofadministration, including controlled release formulations, such assubcutaneous implants. Administration methods include oral, rectal,parenteral (intravenous, intramuscular, subcutaneous), intracisternal,intravaginal, intraperitoneal, intravesical, local (drops, powders,ointments, gels or cream), and by inhalation (a buccal or nasal spray)as appropriate depending on the overall health and condition of thepatient as determined by a physician or veterinary doctor.

Parenteral formulations include pharmaceutically acceptable aqueous ornonaqueous solutions, dispersion, suspensions, emulsions, and sterilepowders for the preparation thereof. Examples of carriers include water,ethanol, polyols (propylene glycol, polyethylene glycol), vegetableoils, and injectable organic esters such as ethyl oleate. Fluidity canbe maintained by the use of a coating such as lecithin, a surfactant, ormaintaining appropriate particle size. Carriers for solid dosage formsinclude (a) fillers or extenders, (b) binders, (c) humectants, (d)disintegrating agents, (e) solution retarders, (f) absorptionaccelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and(j) propellants.

Compositions may also contain adjuvants such as preserving, wetting,emulsifying, and dispensing agents; antimicrobial agents such asparabens, chlorobutanol, phenol, and sorbic acid; isotonic agents suchas a sugar or sodium chloride; absorption-prolonging agents such asaluminum monostearate and gelatin; and absorption-enhancing agents.

3. Combination Therapy

The present invention also provides compositions and methods useful forthe treatment of disorders or conditions modulated, preferablyantagonized, by the histamine H₃ receptor in combination with compoundsthat modulate other receptors including, but not limited to, histamineH₁ and histamine H₂ receptors. The present invention includes compoundsand compositions useful in methods of combination therapy for thetreatment of diseases or conditions modulated by the histamine H₃receptor in combination with compounds that are selective serotoninre-uptake inhibitors (SSRIs), such as PROZAC™, or are selectivenorepinephrine uptake inhibitors. Such combination methods include (a)administering the two or more pharmaceutical agents separatelyformulated and at separate times, and (b) administering the two or moreagents simultaneously in a single formulation or in separateformulations administered more or less at the same time. For example,one aspect is a method of treatment comprising administering at leastone histamine H₃ receptor modulating compound disclosed herein andadministering at least one compound selected from a histamine H₁receptor modulating compound, a histamine H₂ receptor modulatingcompound, a selective serotonin reuptake inhibitor (such as PROZAC™), ora selective norepinephrine uptake inhibiting compound.

4. Related Compounds

The invention provides the disclosed compounds and closely related,pharmaceutically acceptable forms of the disclosed compounds, such assalts, esters, amides, acids, hydrates or solvated forms thereof; maskedor protected forms; and racemic mixtures, or enantiomerically oroptically pure forms.

Pharmaceutically acceptable salts, esters, and amides includecarboxylate salts (e.g., C₁₋₈ alkyl, cycloalkyl, aryl, heteroaryl, ornon-aromatic heterocyclic) amino acid addition salts, esters, and amideswhich are within a reasonable benefit/risk ratio, pharmacologicallyeffective and suitable for contact with the tissues of patients withoutundue toxicity, irritation, or allergic response. Representative saltsinclude hydrobromide, hydrochloride, sulfate, bisulfate, nitrate,acetate, oxalate, valerate, oleate, palmitate, stearate, laurate,borate, benzoate, lactate, phosphate, tosylate, citrate, maleate,fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate,lactiobionate, and laurylsulfonate. These may include alkali metal andalkali earth cations such as sodium, potassium, calcium, and magnesium,as well as non-toxic ammonium, quaternary ammonium, and amine cationssuch as tetramethyl ammonium, methylamine, trimethylamine, andethylamine. See example, S. M. Berge, et al., “Pharmaceutical Salts,” J.Pharm. Sci., 1977, 66:1-19 which is incorporated herein by reference.Representative pharmaceutically acceptable amides of the inventioninclude those derived from ammonia, primary C₁₋₆ alkyl amines andsecondary di(C₁₋₆ alkyl) amines. Secondary amines include 5- or6-membered heterocyclic or heteroaromatic ring moieties containing atleast one nitrogen atom and optionally between 1 and 2 additionalheteroatoms. Preferred amides are derived from ammonia, C₁₋₃ alkylprimary amines, and di (C₁₋₂ alkyl)amines. Representativepharmaceutically acceptable esters of the invention include C₁₋₇ alkyl,C₅₋₇ cycloalkyl, phenyl, and phenyl(C₁₋₆)alkyl esters. Preferred estersinclude methyl esters.

The invention also includes disclosed compounds having one or morefunctional groups (e.g., hydroxyl, amino, or carboxyl) masked by aprotecting group. See, e.g., Greene and Wuts, Protective Groups inOrganic Synthesis, 3^(rd) ed., (1999) John Wiley & Sons, NY. Some ofthese masked or protected compounds are pharmaceutically acceptable;others will be useful as intermediates. Synthetic intermediates andprocesses disclosed herein, and minor modifications thereof, are alsowithin the scope of the invention.

Hydroxyl Protecting Groups

Protection for the hydroxyl group includes methyl ethers, substitutedmethyl ethers, substituted ethyl ethers, substitute benzyl ethers, andsilyl ethers.

Substituted Methyl Ethers

Examples of substituted methyl ethers include methyoxymethyl,methylthiomethyl, t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl,benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl,guaiacolmethyl, t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl,2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl,bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl,tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl,1-methoxycyclohexyl, 4-methoxytetrahydropyranyl,4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranylS,S-dioxido, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl,1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl and2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl.

Substituted Ethyl Ethers

Examples of substituted ethyl ethers include 1-ethoxyethyl,1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl,1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl,t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, andbenzyl.

Substituted Benzyl Ethers

Examples of substituted benzyl ethers include p-methoxybenzyl,3,4-dimethoxybenzyl, onitrobenzyl, p-nitrobenzyl, p-halobenzyl,2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- and 4-picolyl,3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p′-dinitrobenzhydryl,5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl,p-methoxyphenyidiphenylmethyl, di(p-methoxyphenyl)phenylmethyl,tri(p-methoxyphenyl)methyl, 4-(4′-bromophenacyloxy)phenyldiphenylmethyl,4,4′,4″-tris(4,5-dichlorophthalimidophenyl)methyl,4,4′,4″-tris(levulinoyloxyphenyl)methyl,4,4′,4″-tris(benzoyloxyphenyl)methyl,3-(Imidazol-1-ylmethyl)bis(4′,4″-dimethoxyphenyl)methyl,1,1-bis(4-methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl,9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl,1,3-benzodithiolan-2-yl, and benzisothiazolyl S,S-dioxido.

Silyl Ethers

Examples of silyl ethers include trimethylsilyl, triethylsilyl,triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl,dimethylthexylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl,tribenzylsilyl, tri-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, andt-butylmethoxyphenylsilyl.

Esters

In addition to ethers, a hydroxyl group may be protected as an ester.Examples of esters include formate, benzoylformate, acetate,chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate,methoxyacetate, triphenylmethoxyacetate, phenoxyacetate,p-chlorophenoxyacetate, p-P-phenylacetate, 3-phenylpropionate,4-oxopentanoate(levulinate), 4,4-(ethylenedithio)pentanoate, pivaloate,adamantoate, crotonate, 4-methoxycrotonate, benzoate, pphenylbenzoate,2,4,6-trimethylbenzoate(mesitoate).

Carbonates

Examples of carbonate protecting groups include methyl,9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl,2-(phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl,allyl, p-nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl,p-nitrobenzyl, p-nitrobenzyl, S-benzyl thiocarbonate,4-ethoxy-1-naphthyl, and methyl dithiocarbonate.

Assisted Cleavage

Examples of assisted cleavage include 2-iodobenzoate, 4-azidobutyrate,4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate,2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate,4-(methylthiomethoxy)butyrate, and 2-(methylthiomethoxymethyl)benzoate.

Miscellaneous Esters

Examples of miscellaneous esters include2,6-dichloro-4-methylphenoxyacetate,2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate,2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate,isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate(tigloate),o-(methoxycarbonyl)benzoate, p-P-benzoate, α-naphthoate, nitrate, alkylN,N,N′,N′-tetramethylphosphorodiamidate, N-phenylcarbamate, borate,dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate.

Sulfonates

Examples of sulfonates include sulfate, methanesulfonate(mesylate),benzylsulfonate, and tosylate.

Protection for 1,2- and 1,3-Diols

Cyclic Acetals and Ketals

Examples of cyclic acetals and ketals include methylene, ethylidene,1-t-butylethylidene, 1-phenylethylidene, (4-methoxyphenyl)ethylidene,2,2,2-trichloroethylidene, acetonide (isopropylidene), cyclopentylidene,cyclohexylidene, cycloheptylidene, benzylidene, pmethoxybenzylidene,2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene, and2-nitrobenzylidene.

Cyclic Ortho Esters

Examples of cyclic ortho esters include methoxymethylene,ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene,1-ethoxyethylidine, 1,2-dimethoxyethylidene, α-methoxybenzylidene,1-(N,N-dimethylamino)ethylidene derivative,α-(N,N-dimethylamino)benzylidene derivative, and 2-oxacyclopentylidene.

Silyl Derivatives

Examples of silyl derivatives include di- t-butylsilylene group, and1,3-(1,1,3,3-tetraisopropyldisiloxanylidene) derivative.

Amino Protecting Groups

Protection for the amino group includes carbamates, amides, and special—NH protective groups.

Examples of carbamates include methyl and ethyl carbamates, substitutedethyl carbamates, assisted cleavage carbamates, photolytic cleavagecarbamates, urea-type derivatives, and miscellaneous carbamates.

Carbamates

Examples of methyl and ethyl carbamates include methyl and ethyl,9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl,9-(2,7-dibromo)fluorenylmethyl,2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl,and 4-methoxyphenacyl.

Substituted Ethyl

Examples of substituted ethyl carbamates include 2,2,2-trichloroethyl,2-trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl,1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl,1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1-(4-biphenylyl)ethyl,1-(3,5-di-t-butylphenyl)-1-methylethyl, 2-(2′- and 4′-pyridyl)ethyl,2-(N,N-dicyclohexylcarboxamido)ethyl, t-butyl, 1-adamantyl, vinyl,allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl,N-hydroxypiperidinyl, alkyldithio, benzyl, p-methoxybenzyl,p-nitrobenzyl, p-bromobenzyl, p-chlorobenzyl, 2,4-dichlorobenzyl,4-methylsulfinylbenzyl, 9-anthrylmethyl and diphenylmethyl.

Assisted Cleavage

Examples of assisted cleavage include 2-methylthioethyl,2-methylsulfonylethyl, 2-(p-toluenesulfonyl)ethyl,[2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl,2-phosphonioethyl, 2-triphenylphosphonioisopropyl,1,1-dimethyl-2-cyanoethyl, m-chloro-p-acyloxybenzyl,p-(dihydroxyboryl)benzyl, 5-benzisoxazolylmethyl, and2-(trifluoromethyl)-6-chromonylmethyl.

Photolytic Cleavage

Examples of photolytic cleavage include m-nitrophenyl,3,5-dimethoxybenzyl, onitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, andphenyl(o-nitrophenyl)methyl.

Urea-Type Derivatives

Examples of urea-type derivatives include phenothiazinyl-(10)-carbonylderivative, N′-p-toluenesulfonylaminocarbonyl, andN′-phenylaminothiocarbonyl.

Miscellaneous Carbamates

Examples of miscellaneous carbamates include t-amyl, S-benzylthiocarbamate, p-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl,cyclopropylmethyl, p-decyloxybenzyl, diisopropylmethyl,2,2-dimethoxycarbonylvinyl, o-(N,N-dimethylcarboxamido)benzyl,1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl, 1,1-dimethylpropynyl,di(2-pyridyl)methyl, 2-furanylmethyl, 2-iodoethyl, isobornyl, isobutyl,isonicotinyl, p-(p′-methoxyphenylazo)benzyl, 1-methylcyclobutyl,1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl,1-methyl-1-(3,5-dimethoxyphenyl)ethyl,1-methyl-1-(p-phenylazophenyl)ethyl, 1-methyl-1-phenylethyl,1-methyl-1-(4-pyridyl)ethyl, phenyl, p-(phenylazo)benzyl,2,4,6-tri-t-butylphenyl, 4-(trimethylammonium)benzyl, and2,4,6-trimethylbenzyl.

Examples of amides include:

Amides

N-formyl, N-acetyl, N-chloroacetyl, N-trichloroacetyl,N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl, N-picolinoyl,N-3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, N-benzoyl,N-p-phenylbenzoyl.

Assisted Cleavage

N-o-nitrophenylacetyl, N-o-nitrophenoxyacetyl, N-acetoacetyl,(N′-dithiobenzyloxycarbonylamino)acetyl, N-3-(p-hydroxyphenyl)propionyl,N-3-(o-nitrophenyl)propionyl, N-2-methyl-2-(o-nitrophenoxy)propionyl,N-2-methyl-2-(o-phenylazophenoxy)propionyl, N-4-chlorobutyryl,N-3-methyl-3-nitrobutyryl, N-o-nitrocinnamoyl, N-acetylmethioninederivative, N-o-nitrobenzoyl, N-o-(benzoyloxymethyl)benzoyl, and4,5-diphenyl-3-oxazolin-2-one.

Cyclic Imide Derivatives

N-phthalimide, N-dithiasuccinoyl, N-2,3-diphenylmaleoyl,N-2,5-dimethylpyrrolyl, N-1,1,4,4-tetramethyldisilylazacyclopentaneadduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one,5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, and1-substituted 3,5-dinitro-4-pyridonyl.

Special—NH Protective Groups

Examples of special NH protective groups include

N-Alkyl and N-Aryl Amines

N-methyl, N-allyl, N-[2-(trimethylsilyl)ethoxy]methyl,N-3-acetoxypropyl, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl),quaternary ammonium salts, N-benzyl, N-di(4-methoxyphenyl)methyl,N-5-dibenzosuberyl, N-triphenylmethyl,N-(4-methoxyphenyl)diphenylmethyl, N-9-phenylfluorenyl,N-2,7-dichloro-9-fluorenylmethylene, N-ferrocenylmethyl, andN-2-picolylamine N′-oxide.

Imine Derivatives

N-1,1-dimethylthiomethylene, N-benzylidene, N-p-methoxybenzylidene,N-diphenylmethylene, N-[(2-pyridyl)mesityl]methylene, andN-(N′,N′-dimethylaminomethylene).

Protection for the Carbonyl Group

Acyclic Acetals and Ketals

Examples of acyclic acetals and ketals include dimethyl,bis(2,2,2-trichloroethyl), dibenzyl, bis(2-nitrobenzyl) and diacetyl.

Cyclic Acetals and Ketals

Examples of cyclic acetals and ketals include 1,3-dioxanes,5-methylene-1,3-dioxane, 5,5-dibromo-1,3-dioxane,5-(2-pyridyl)-1,3-dioxane, 1,3-dioxolanes, 4-bromomethyl-1,3-dioxolane,4-(3-butenyl)-1,3-dioxolane, 4-phenyl-1,3-dioxolane,4-(2-nitrophenyl)-1,3-dioxolane, 4,5-dimethoxymethyl-1,3-dioxolane,O,O′-phenylenedioxy and 1,5-dihydro-3H-2,4-benzodioxepin.

Acyclic Dithio Acetals and Ketals

Examples of acyclic dithio acetals and ketals include S,S′-dimethyl,S,S′-diethyl, S,S′-dipropyl, S,S′-dibutyl, S,S′-dipentyl, S,S′-diphenyl,S,S′-dibenzyl and S,S′-diacetyl.

Cyclic Dithio Acetals and Ketals

Examples of cyclic dithio acetals and ketals include 1,3-dithiane,1,3-dithiolane and 1,5-dihydro-3H-2,4-benzodithiepin.

Acyclic Monothio Acetals and Ketals

Examples of acyclic monothio acetals and ketals includeO-trimethylsilyl-S-alkyl, O-methyl-S-alkyl or —S-phenyl andO-methyl-S-2-(methylthio)ethyl.

Cyclic Monothio Acetals and Ketals

Examples of cyclic monothio acetals and ketals include 1,3-oxathiolanes.

Miscellaneous Derivatives

O-Substituted Cyanohydrins

Examples of O-substituted cyanohydrins include O-acetyl,O-trimethylsilyl, O-1-ethoxyethyl and O-tetrahydropyranyl.

Substituted Hydrazones

Examples of substituted hydrazones include N,N-dimethyl and2,4-dinitrophenyl.

Oxime Derivatives

Examples of oxime derivatives include O-methyl, O-benzyl andO-phenylthiomethyl.

Imines

Substituted Methylene Derivatives, Cyclic Derivatives

Examples of substituted methylene and cyclic derivatives includeoxazolidines, 1-methyl-2-(1′-hydroxyalkyl)imidazoles,N,N′-dimethylimidazolidines, 2,3-dihydro-1,3-benzothiazoles,diethylamine adducts, and methylaluminumbis(2,6-di-t-butyl-4-methylphenoxide)(MAD)complex.

Protection for the Carboxyl Group

Esters

Examples of esters include the following.

Substituted Methyl Esters

Examples of substituted methyl esters include 9-fluorenylmethyl,methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl,methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl,phenacyl, p-bromophenacyl, α-methylphenacyl, p-methoxyphenacyl,carboxamidomethyl, and N-phthalimidomethyl.

2-Substituted Ethyl Esters

Examples of 2-substituted ethyl esters include 2,2,2-trichloroethyl,2-haloethyl, ω-chloroalkyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl,1,3-dithianyl-2-methyl, 2-(p-nitrophenylsulfenyl)ethyl,2-(p-toluenesulfonyl)ethyl, 2-(2′-pyridyl)ethyl,2-(diphenylphosphino)ethyl, 1-methyl-1-phenylethyl, t-butyl,cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl,4-(trimethylsilyl)-2-buten-1-yl, cinnamyl, α-methylcinnamyl, phenyl,p-(methylmercapto)phenyl and benzyl.

Substituted Benzyl Esters

Examples of substituted benzyl esters include triphenylmethyl,diphenylmethyl, bis(onitrophenyl)methyl, 9-anthrylmethyl,2-(9,10-dioxo)anthrylmethyl, 5-dibenzosuberyl, 1-pyrenylmethyl,2-(trifluoromethyl)-6-chromylmethyl, 2,4,6-trimethylbenzyl,p-bromobenzyl, o-nitrobenzyl, p-nitrobenzyl, p-methoxybenzyl,2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfobenzyl, piperonyl,4-picolyl and p-P-benzyl.

Silyl Esters

Examples of silyl esters include trimethylsilyl, triethylsilyl,t-butyldimethylsilyl, i-propyldimethylsilyl, phenyidimethylsilyl anddi-t-butylmethylsilyl.

Activated Esters

Examples of activated esters include thiols.

Miscellaneous Derivatives

Examples of miscellaneous derivatives include oxazoles,2-alkyl-1,3-oxazolines, 4-alkyl-5-oxo-1,3-oxazolidines,5-alkyl-4-oxo-1,3-dioxolanes, ortho esters, phenyl group andpentaaminocobalt(III) complex.

Stannyl Esters

Examples of stannyl esters include triethylstannyl andtri-n-butylstannyl.

Amides and Hydrazides

Amides

Examples of amides include N,N-dimethyl, pyrrolidinyl, piperidinyl,5,6-dihydrophenanthridinyl, onitroanilides, N-7-nitroindolyl,N-8-Nitro-1,2,3,4-tetrahydroquinolyl, and p-P-benzenesulfonamides.

Hydrazides

Examples of hydrazides include N-phenyl and N,N′-diisopropyl hydrazides.

E. Synthetic Chemical Examples

The following examples were prepared according to the Schemes herein,and also using guidance provided by U.S. Pat. No. 4,727,145 and Sanfilippo, et al. J. Med. Chem. 188, 31, 2221 (1988).

EXAMPLE 1

Analysis: Calc'd for C₂₁H₂₆N₄O 3HCl 0.5H₂O; C, 6.45; H, 53; N, 11.95.Found: C, 6.63; H, 53.74; N, 11.66.

EXAMPLE 2

Analysis: Calc'd for C₁₉H₂₁N₃O₂ 3HCl; C, 5.59; H, 53.73; N, 9.71. Found:C, 5.59; H, 52.99; N, 9.8.

EXAMPLE 3

Analysis: Calc'd for C₂₁H₂₅N₃O₂ 2HCl; C, 6.41; H, 59.44; N, 9.9. Found:C, 6.52; H, 59.7; N, 9.55.

EXAMPLE 4

Analysis: Calc'd for C₂₀H₂₂N₄O 2HCl; C, 5.94; H, 58.97; N, 13.75. Found:C, 5.54; H, 59.27; N, 13.42.

EXAMPLE 5

Analysis: Calc'd for C₂₄H₃₃N₃O 3HCl; C, 7.42; H, 58.96; N, 8.59. Found:C, 7.63; H, 58.7; N, 8.4.

EXAMPLE 6

Analysis: Calc'd for C₂₁H₂₆N₄O 2HCl; C, 6.67; H, 59.58; N, 13.23. Found:C, 6.86; H, 59.78; N, 12.96.

EXAMPLE 7

Analysis: Calc'd for C₂₀H₂₆N₄O 3HCl; C, 6.77; H, 55.63; N, 12.97. Found:C, 6.62; H, 55.92; N, 12.8.

EXAMPLE 8

Step A Preparation of p-chloropropoxyacetophenone

A mixture of p-hydroxyacetophenone (15 g) and 1-bromo-3-chloropropane(12 mL) in acetone (200 mL) was treated with potassium carbonate (17 g).The mixture was stirred at reflux temperature for 18 hours. The reactionwas cooled to ambient temperature and filtered. The filtrate wasconcentrated in vacuo. The residue was dissolved in ether, washed withwater, dried over sodium sulfate, filtered and evaporated to yield thetitle compound (23 g).

Step B Preparation of alpha-bromo-4-chloropropoxyacetophenone

A solution of the product of Step A (2.0 g) in ether (10 mL) was treatedwith bromine (0.48 mL) and the mixture stirred for 18 hours. The mixturewas poured into saturated sodium bicarbonate solution (50 mL) and theorganic layer was separated. The aqueous layer was washed with a freshportion of ether (50 mL) and the combined organic layers were washedwith brine (50 mL), dried over magnesium sulfate, filtered, andevaporated to yield the title compound (2.7 g).

Step C Preparation of2-(4-chloropropoxyphenyl)-7-methylimidazo[1,2-a]pyridine

A solution of the product of Step B (2.0 g) and 2-amino-4-picoline (0.74g) in ethanol (8 mL) was heated at reflux temperature for 2 hours. Thereaction mixture was cooled to ambient temperature and the solventevaporated in vacuo. The residue was dissolved in dichloromethane (75mL), washed with saturated sodium bicarbonate (2×75 mL), brine (75 mL),dried over magnesium sulfate, filtered and evaporated. The residue waspurified via silica gel chromatography (ethyl acetate/hexane) to givethe title compound (1.3 g).

Step D Preparation of2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine

The product of Step C (0.2 g) and piperidine (2.0 mL) were heated atreflux temperature for 5 hours. The reaction was cooled to ambienttemperature and partitioned between ethyl acetate (10 mL) and saturatedsodium bicarbonate solution (10 mL). The aqueous portion was extractedwith additional ethyl acetate (10 mL) and the organic portions combined.The organic portions were dried over magnesium sulfate, filtered andevaporated. The residue was purified via silica gel chromatography(dichloromethane/methanol) to give the title compound (0.21 g). Thiscompound can also be named as7-(methyl-2-[4-(3-piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine.Treatment with 2M HCl in ether afforded the dihydrochloride. ¹H NMR(CD₃OD) 88.67 (d, J=7.5 Hz, 1H), 8.41 (s, 1H), 7.84 (m, 2H), 7.71 (s,1H), 7.36 (dd, J=6.9 Hz, J=1.4 Hz, 1H), 7.16 (m, 2H), 4.22 (t, J=5.8 Hz,2H), 3.64 (d, J=12.5 Hz, 2H), 3.35 (m, 2H), 3.04 (m, 2H), 2.62 (s, 3H),2.34 (m, 2H), 1.99 (m, 2H), 1.86 (m, 3H), 1.59 (m, 1H); ¹³C NMR (CD₃OD)δ 161.0, 147.1, 141.1, 136.2, 128.5, 128.2, 120.3, 119.3, 115.8, 110.6,109.9, 65.8, 55.0, 53.8, 24.5, 23.6, 22.1, 21.2, MS (M+H)=350.2Analysis: Calc'd for C₂₂H₂₇N₃O .2HCl.(2H₂O) C, 57.64; H, 7.26; N, 9.17;Found: C, 57.68; H, 7.13; N, 9.16.

EXAMPLE 9

Step A Preparation of p-chloropropoxy-3-methylacetophenone

A mixture of p-hydroxy-3-methylacetophenone (4.7 g) and1-bromo-3-chloropropane (12 mL) in methanol (20 mL) was treated withpotassium hydroxide (5.3 g). The mixture was stirred at refluxtemperature for 16 hours. The solvent was evaporated in vacuo and theresidue partitioned between water (20 mL) and ether (50 mL). The organicfraction was washed with water (3×20 mL), dried over sodium sulfate,filtered and evaporated to give the crude material containing the titlecompound that was used without further purification.

Step B Preparation of alpha-bromo-4′-chloropropoxy-3-methylacetophenone

A solution of the product of Step A (6.7 g) in ether (80 mL) was treatedwith bromine (16 mL) and the mixture stirred for 14 hours. The mixturewas poured into saturated sodium bicarbonate solution (100 mL). Theorganic layer was separated, washed with additional saturated sodiumbicarbonate solution (100 mL), water (100 mL), dried over sodiumsulfate, filtered and evaporated to give the crude material containingthe title compound that was used without further purification.

Step C Preparation of2-(4′-chloropropoxy-3-methylphenyl)-8-methylimidazo[1,2-a]pyridine

A solution of the product of Step B (9 g) and 2-amino-3-picoline (3 g)in ethanol (40 mL) was heated at reflux temperature for 4 hours. Thereaction mixture was cooled to ambient temperature and the solventevaporated in vacuo. The residue was purified via silica gelchromatography (ethyl acetate/hexane) to give the title compound (2.8g).

Step D Preparation of2-(4-Piperidylpropoxy-3-methylphenyl)-8-methylimidazo[1,2-a]pyridine

The product of Step C (0.5 g) and piperidine (8 mL) were heated atreflux temperature for 12 hours. The reaction was cooled to ambienttemperature and the excess piperidine was removed in vacuo. The residuewas dissolved in ethyl acetate (100 mL) and washed with water, driedover magnesium sulfate, filtered and evaporated. The residue waspurified via silica gel chromatography (dichloromethane/methanol) togive the title compound (0.4 g). MS (ESI) m/z 364.2 (MH⁺); ¹H NMR (400MHz, CDCl₃) δ 7.96 (d, J=6.5 Hz, 1H), 7.74 (t, J=6.2 Hz, 3H), 6.90 (dd,J=6.7 and 8.4 Hz, 2H), 6.65 (t, J=6.8 Hz, 1H), 4.05 (t, J=6.7 Hz, 2H),2.66 (s, 3H), 2.54 (t, J=7.4 Hz, 2H), 2.43 (bs, 4H), 2.29 (s, 3H), 2.02(m, 2H), 1.61 (m, 4H), 1.45 (m, 2H).

EXAMPLE 10

Step A Preparation of alpha-bromo-4-hydroxyacetophenone

Bromine (17.6 g, 110 mmol) was added dropwise to a 0° C. solution of4-hydroxyacetophenone (15 g, 110 mmol) in ether (200 mL) over 20minutes. The mixture was stirred for 1 hour and poured carefully intosaturated sodium bicarbonate solution (500 mL). The organics were washedwith saturated sodium bicarbonate solution, dried over magnesium sulfateand concentrated in vacuo. The crude product was then recrystallizedfrom ether to afford the title compound (14.1 g).

Step B Preparation of2-(4-hydroxyphenyl)-7-methylimidazo[1,2a]pyridinehydrobromide

The product of Step A (430 mg, 2.0 mmol), and 2-picoline (188 mg, 2.0mmol) were mixed in 2-propanol (4.0 mL) and stirred for 18 hr. Theresulting crystals were collected and washed with 2-propanol and driedunder vacuum to afford the title compound (287 mg).

Step C Preparation of2-(4-(N-(ethyl)anilinoethoxy)phenyl)imidazo[1,2-a]pyridine

A mixture of immobilized triphenylphisphine resin (300 mg, 0.9 meq(Fluka)), and the product of Step B (84 mg, 0.30 mmol) intetrahydrofuran (2.5 mL) was treated with 2-(N-ethylanilino)ethanol (149mg, 0.9 μmol) followed by diethyl azidodicarboxylate (0.142 mL, 0.9mmol). The reaction was shaken for 20 hr. and filtered. The filtrate wasconcentrated in vacuo and the residue purified by silica gelchromatography (hexane/ethyl acetate) to afford the title compound (34mg). MS (ESI) m/z 358 (MH⁺); ¹H-NMR (CDCl₃) δ 8.14 (d, 1H), 7.90 (d,2H), 7.80 (s, 1H), 7.66 (bd, 1H), 7.28 (d, 1H), 7.25 (d, 1H), 7.19 (t,1H), 6.99 (d, 2H), 6.80 (t, 1H, 6.78 (d, 1H), 6.72 (t, 1H), 4.38 (t,2H), 3.55 (t, 2H), 3.04 (q, 2H), 1.46 (t, 3H).

EXAMPLE 11

The title compound was obtained (78 mg) by the same general method asExample 10, by substituting 4-hydroxy-3-methylacetophenone for4-hydroxyacetophenone and 2-ethoxy-1-methylpyrrolidine for2-(N-ethylanilino) ethanol. MS (ESI) m/z 336 (MH⁺); ¹H-NMR (CDCl₃) δ8.02 (d, 1H), 7.69 (s, 1H), 7.68 (d, 1H), 7.64 (dd, 1H), 7.52, (d, 1H),7.06 (dd, 1H), 6.80 (d, 1H), 6.66 (t, 1H), 3.98 (m, 2H), 3.49 (dt, 1H),3.00 (m, 2H), 2.28 (s, 3H), 2.20 (s, 3H), 2.0-1.5 (m, 6H).

EXAMPLE 12

The title compound was obtained (28 mg) by the same general method asExample 10, by substituting 4-hydroxy-3-methylacetophenone for4-hydroxyacetophenone and 1-propoxypiperidine for2-(N-ethylanilino)ethanol. MS (ESI) m/z 350 (MH⁺); ¹H-NMR (CDCl₃) δ 8.11(d, 1H), 7.79 (s, 1H), 7.76 (s, 1H), 7.73 (d, 1H), 7.62 (d, 1H), 7.15(dd, 1H), 6.89 (d, 1H), 6.77 (t, 1H), 4.06 (t, 2H), 2.45 (m, 6H), 2.29(s, 3H), 1.62 (m, 6H), 1.45 (m, 2H).

EXAMPLE 13

The product of Example 26 Step C (112 mg) and pyrrolidine (1.1 mL) wereheated at 85° C. for 3 hours. The reaction was cooled to ambienttemperature and partitioned between ethyl acetate (10 mL) and saturatedsodium bicarbonate solution (10 mL). The aqueous portion was extractedtwice with additional ethyl acetate (10 mL) and once withdichloromethane (10 mL). The organic portions were combined and washedwith brine and evaporated. The residue was purified via silica gelchromatography (dichloromethane/2M ammonia in methanol) to give thetitle compound (80 mg). ¹H-NMR (CDCl₃) δ 7.98 (d, J=7.0 Hz, 1H), 7.73(s, 1H), 7.56 (d, J=2.0 Hz, 1H), 7.42 (dd, J=8.0 Hz, J=2.0 Hz, 1H), 7.38(br s, 1H), 6.96 (d, J=8.0 Hz, 1H), 6.60 (dd, J=7.0 Hz, J=1.5 Hz, 1H),4.15 (t , J=7.0 Hz, 2H), 3.99 (s, 3H), 2.67 (t, J=7.5 Hz, 2H), 2.55 (m,4H), 2.40 (s, 3H), 2.12 (m, 2H), 1.80 (m, 4H).

EXAMPLE 14

The product of Example 26 Step C (130 mg) and hexamethyleneimine (1.5mL) were heated at 100° C. for 1.5 hours. The reaction was cooled toambient temperature and partitioned between ethyl acetate (10 mL) andsaturated sodium bicarbonate solution (10 mL). The aqueous portion wasextracted twice with additional ethyl acetate (10 mL) and once withdichloromethane (10 mL). The organic portions were combined and washedwith brine and evaporated. The residue was purified via silica gelchromatography (dichloromethane/2M ammonia in methanol) to give thetitle compound (57 mg). ¹H-NMR (CD₃OD) δ 8.18 (d, J=7.0 Hz, 1H), 7.94(s, 1H), 7.51 (d, J=2.0 Hz, 1H), 7.38 (dd, J=8.0 Hz, J=2.0 Hz, 1H), 7.27(s, 1H), 6.94 (d, J=8.0 Hz, 1H), 6.70 (dd, J=7.0 Hz, J=1.5 Hz, 1H), 4.01(t, J=6.0 Hz, 2H), 3.91 (s, 3H), 2.70 (m, 6H), 2.38 (s, 3H), 1.97 (m,2H), 1.63 (m, 8H).

EXAMPLE 15

Step A Preparation 1-[3-(3-Chloro-propoxy)-phenyl]-ethanone

A mixture of 3′-hydroxyacetophenone (5 g) and 1-bromo-3-chloropropane(5.0 mL) in acetone (40 mL) was treated with potassium carbonate (8.1g). The mixture was stirred at reflux temperature for 17 hours. Thereaction was cooled to ambient temperature and filtered. The filtratewas concentrated in vacuo. The residue was partitioned betweendichloromethane (50 mL) and H₂O (50 mL). The aqueous phase was washedwith two fresh portions of dichloromethane. The combined organic phaseswere washed with brine, dried over magnesium sulfate, filtered andevaporated to yield the title compound (8.6 g) which was used withoutfurther purification.

Step B Preparation of 2-Bromo-1-[3-(3-chloro-propoxy)-phenyl]-ethanone

A solution of the product of Step A (2.1 g) in ether (11 mL) was treatedwith bromine (0.53 mL) and the mixture stirred for 26 hours. The mixturewas poured into saturated sodium bicarbonate solution (50 mL) and theorganic layer was separated. The aqueous layer was washed with a freshportion of ether (50 mL) and the combined organic layers were washedwith brine (50 mL), dried over magnesium sulfate, filtered, andevaporated to yield the title compound (2.8 g).

Step C Preparation of2-[3-(3-Chloro-propoxy)-phenyl]-7-methyl-imidazo[1,2-a]pyridine

A solution of the product of Step B (2.6 g) and 2-amino-4-picoline (0.96g) in ethanol (10 mL) was heated at 73° C. for 2 hours. The reactionmixture was cooled to ambient temperature and the solvent evaporated invacuo. The residue was dissolved in dichloromethane (75 mL), washed withsaturated sodium bicarbonate solution (2×75 mL), brine (75 mL), driedover magnesium sulfate, filtered and evaporated. The residue waspurified via silica gel chromatography (ethyl acetate/hexane) to givethe title compound (1.3 g).

Step D7-Methyl-2-[3-(3-piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine

The product of Step C (271 mg) and piperidine (2.0 mL) were heated at100° C. for 2 hours. The reaction was cooled to ambient temperature andpartitioned between ethyl acetate (10 mL) and saturated sodiumbicarbonate solution (10 mL). The aqueous portion was extracted with afresh portion of ethyl acetate (10 mL) and the organic portions combinedand washed with brine (10 mL). The organic portions were dried overmagnesium sulfate, filtered and evaporated. The residue was purified viasilica gel chromatography (dichloromethane/methanol) to give the titlecompound (193 mg). ¹H-NMR (CD₃OD) δ 8.27 (d, J=7.0 Hz, 1H), 8.08 (s,1H), 7.46 (m, 2H), 7.31 (m, 2H), 6.88 (m, 1H), 6.76 (m, 1H), 4.09 (t,J=6.0 Hz, 2H), 2.58 (m, 6H), 2.42 (s, 3H), 2.04 (m, 2H), 1.65 (m, 4H),1.51 (m, 2H).

EXAMPLE 16

Step A Preparation of2-[4-(3-Chloro-propoxy)-phenyl]-imidazo[1,2-a]pyridine

A solution of the product of Example 8 Step B (402 mg) and2-aminopyridine (130 mg) in EtOH (2 mL) was heated at 73° C. for 2.5hours. The reaction mixture was cooled to ambient temperature and thesolvent evaporated in vacuo. The residue was dissolved indichloromethane (15 mL), washed with saturated sodium bicarbonatesolution (2×15 mL), brine (15 mL), dried over magnesium sulfate,filtered and evaporated. The residue was purified via silica gelchromatography (ethyl acetate/hexanes) to give the title compound (235mg).

Step B Preparation of2-[4-(3-Chloro-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine

To a Parr bottle charged with a mixture of platinum (IV) oxide (30 mg)in ethanol (3 mL) was added a solution of the product of Step A (90 mg)in methanol (6 ml). The mixture was hydrogenated at 40 psi for 4 hoursand filtered through a Celite pad which was rinsed with severaladditional milliliters of methanol and ethanol. The filtrate wascollected and evaporated in vacuo to yield the title compound (88 mg)which was used without further purification.

Step C Preparation of2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine

The product of Step B (83 mg) and piperidine (1.0 mL) were heated at100° C. for 1.5 hours. The reaction was cooled to ambient temperatureand partitioned between ethyl acetate (10 mL) and saturated sodiumbicarbonate solution (10 mL). The aqueous portion was extracted with afresh portion of ethyl acetate (2×10 mL) and the organic portionscombined and washed with brine (10 mL). The organic portions were driedover magnesium sulfate, filtered and evaporated. The residue waspurified via silica gel chromatography (dichloromethane/methanol) togive the title compound (35 mg). ¹H-NMR (CDCl₃) δ 7.61 (m, 2H), 7.16 (s,1H), 6.92 (m, 2H), 4.01 (m, 4H), 2.84 (t, J=6.0 Hz, 2H), 2.72 (m, 6H),2.00 (m, 6H), 1.68 (m, 4H), 1.56 (m, 2H).

EXAMPLE 17

Step A Preparation of2-[4-(3-Chloro-propoxy)-2-methyl-phenyl]-7-methyl-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine

To a Parr bottle charged with a mixture of platinum (IV) oxide (35 mg)in ethanol (3 mL) was added a solution of the product of Example 22 StepC (104 mg) in methanol (7 ml). The mixture was hydrogenated at 45 psifor 3 hours and filtered through a Celite pad which was rinsed withseveral additional milliliters of methanol and ethanol. The filtrate wascollected and evaporated in vacuo to yield a residue which was purifiedvia silica gel chromatography (dichloromethane/methanol) to give thetitle compound (50 mg).

Step B Preparation of7-Methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine

The product of Step A (49 mg) and piperidine (1.0 mL) were heated at100° C. for 2 hours. The reaction was cooled to ambient temperature andpartitioned between ethyl acetate (10 mL) and saturated sodiumbicarbonate solution (10 mL). The aqueous portion was extracted with afresh portion of ethyl acetate (2×10 mL) and the organic portionscombined and washed with brine (10 mL). The organic portions were driedover magnesium sulfate, filtered and evaporated. The residue waspurified via silica gel chromatography (dichloromethane/methanol) togive the title compound (45 mg). ¹H-NMR (CD₃OD) δ 7.47 (d, J=8.4 Hz,1H), 6.99 (s, 1H), 6.78 (m, 2H), 4.13 (m, 1H), 4.07 (t, J=6.0 Hz, 2H),3.98 (m, 1H), 2.99 (m, 1H), 2.89 (m, 6H), 2.41 (m, 4H), 2.10 (m, 4H),1.75 (m, 5H), 1.60 (m, 2H), 1.18 (d, J=6.5 Hz, 3H).

EXAMPLE 18

The product of Step C, Example 8 (126 mg) and pyrrolidine (1.5 mL) wereheated at 85° C. for 4 hours. The reaction was cooled to ambienttemperature and partitioned between ethyl acetate (6 mL) andhalf-saturated sodium bicarbonate solution (6 mL). The aqueous portionwas extracted with additional ethyl acetate (6 mL) and the organicportions combined and evaporated. The residue was purified via silicagel chromatography (dichloromethane/methanol) to give the title compound(50.3 mg). ¹H-NMR (CD₃OD) δ 8.18 (d, 7.0 Hz, 1H), 7.91 (s, 1H), 7.77 (m,2H), 7.25 (s, 1H), 6.94 (m, 2H), 6.68 (m, 1H), 4.01 (t, J=6.0 Hz, 2H),2.71 (m, 2H), 2.64 (m, 4H), 2.37 (s, 3H), 2.01 (m, 2H), 1.83 (m, 4H).

EXAMPLE 19

The product of Step C, Example 8 (100 mg) and hexamethyleneimine (1.5mL) were heated at 100° C. for 2 hours. The reaction was cooled toambient temperature and partitioned between ethyl acetate (6 mL) andsaturated sodium bicarbonate solution (6 mL). The aqueous portion wasextracted with additional ethyl acetate (6 mL). The organic portionswere combined, washed with brine and evaporated. The residue waspurified via silica gel chromatography (dichloromethane/methanol) togive the title compound (60 mg). ¹H-NMR (CD₃OD) δ 8.15 (d, J=7.0 Hz,1H), 7.88 (s, 1H), 7.76 (m, 2H), 7.23 (s, 1H), 6.92 (m, 2H), 6.65 (m,1H), 3.97 (t, J=6.0 Hz, 2H), 2.78 (m, 6H), 2.34 (s, 3H), 1.97 (m, 2H),1.64 (m, 8H).

EXAMPLE 20

Step A Preparation of 2′-fluoro-4′-chloropropoxyacetophenone

A mixture of 2′-fluoro-4-hydroxy-acetophenone (5.0 g) and1-bromo-3-chloropropane (4.5 mL) in acetone (35 mL) was treated withpotassium carbonate (7.2 g). The mixture was stirred at 52° C. forapproximately 18 hours. The reaction mixture was filtered and thefiltrate collected and evaporated. The residue was partitioned betweendichloromethane (75 mL) and water (75 mL). The aqueous fraction waswashed twice with fresh portions of dichloromethane (75 mL). The organicfractions were combined, washed with brine, and evaporated to give thetitle compound which was used without further purification.

Step B Preparation of alpha-bromo-2′-fluoro-4′-chloropropoxyacetophenone

A solution of the product of Step A (2.3 g) in ether (10 mL) was treatedwith bromine (0.51 mL) and the mixture stirred for approximately 17hours. The mixture was slowly poured into saturated sodium bicarbonatesolution (40 mL) and then the organic layer was separated. The aqueouslayer was washed with a fresh portion of ether (40 mL). The combinedorganic layers were washed with a fresh portion of water (50 mL), driedover magnesium sulfate, filtered and evaporated to give the titlecompound (3.1 g).

Step C Preparation of2-(4′-chloropropoxy-2′fluorophenyl)-7-methylimidazo[1,2-a]pyridine

A solution of the product of Step B (1.0 g) and 2-amino-4-picoline(0.357 g) in ethanol (4 mL) was heated at 73° C. for 18 hours. Thereaction mixture was cooled to ambient temperature and the solventevaporated in vacuo. A portion of the residue was purified via silicagel chromatography (ethyl acetate/hexane) directly. The remainder of theresidue was dissolved in methanol/dichloromethane and treated withDowex® 550A basic resin (Aldrich, Milwaukee, Wis.) for 10 minutes. Theresin was removed via filtration and the filtrate evaporated prior tosilica gel chromatography (ethyl acetate/hexane). The combined material(0.42 g) containing the title compound was used without furtherpurification.

Step D Preparation of2-(4′-piperidinopropoxy-2′fluorophenyl)-7-methylimidazo[1,2-a]pyridine

The product of Step C (118 mg) and piperidine (1.5 mL) were heated at100° C. for 2.5 hours. The reaction was cooled to ambient temperatureand partitioned between ethyl acetate (10 mL) and saturated sodiumbicarbonate solution (10 mL). The aqueous portion was extracted withadditional ethyl acetate (10 mL) and the organic portions combined andevaporated. The residue was purified via silica gel chromatography(dichloromethane/methanol) to give the title compound (130 mg). ¹H-NMR(CD₃OD) δ 8.22 (d, J=8.0 Hz, 1H), 7.98 (m, 2H), 7.27 (s, 1H), 6.76 (m,3H), 4.00 (t, J=6.0 Hz, 2H), 2.48 (m, 6H), 2.38 (s, 3H), 1.96 (m, 2H),1.61 (m, 4H), 1.47 (m, 2H).

EXAMPLE 21

The product of Step C, Example 20 (56 mg) and hexamethyleneimine (1.0mL) were heated at 100° C. for 2 hours. The reaction was cooled toambient temperature and partitioned between ethyl acetate (10 mL) andsaturated sodium bicarbonate solution (10 mL). The aqueous portion wasextracted with additional ethyl acetate (10 mL). The organic portionswere combined and evaporated. The residue was purified via silica gelchromatography (dichloromethane/methanol) to give the title compound (40mg). ¹H-NMR (CD₃OD) δ 8.23 (d, J=7.0 Hz, 1H), 7.98 (m, 2H), 7.27 (s,1H), 6.76 (m, 3H), 4.01 (t, J=6.0 Hz, 2H), 2.66 (m, 6H), 2.38 (s, 3H),1.94 (m, 2H), 1.64 (m, 8H).

EXAMPLE 22

Step A Preparation of 2′-methyl-4′-chloropropoxyacetophenone

A mixture of 4′-hydroxy-2′-methyl-acetophenone (10.5 g) and1-bromo-3-chloropropane (7.6 mL) in acetone (70 mL) was treated withpotassium carbonate (14.5 g). The mixture was stirred at 50° C. forapproximately 18 hours. The reaction mixture was cooled to ambienttemperature and partitioned between dichloromethane (200 mL) and water(200 mL). The aqueous layer was washed twice with fresh portions ofdichloromethane (200 mL) and brine was used to break any emulsions. Theorganic fractions were combined, dried over sodium sulfate, andevaporated. The residue was re-dissolved in dichloromethane (100 mL) andwashed with 0.5 M sodium hydroxide (100 mL) and brine (100 mL), driedover magnesium sulfate, filtered and evaporated to give the titlecompound which was used without further purification.

Step B Preparation of alpha-bromo-2′-methyl-4′-chloropropoxyacetophenone

A solution of the product of Step A (9.33 g) in ether (42 mL) wastreated with bromine (2.1 mL) and the mixture stirred for approximately17 hours. The mixture was slowly poured into saturated sodiumbicarbonate solution (100 mL) and then the organic layer was separated.The aqueous layer was washed with a fresh portion of ether (100 mL). Thecombined organic layers were washed with a fresh portion of water (100mL), dried over magnesium sulfate, filtered and evaporated to give thetitle compound (11 g).

Step C2-(4′-chloropropoxy-2′-methylphenyl)-7-methylimidazo[1,2-a]pyridine

A solution of the product of Step B (6.77 g) and 2-amino-4-picoline (2.4g) in ethanol (22 mL) was heated at 72° C. for 10 hours. The reactionmixture was cooled to ambient temperature and dissolved inmethanol/dichloromethane and treated with Dowex® 550A basic resin untilthe pH of the mixture was 7. The resin was removed via filtration andthe filtrate evaporated. The title compound was precipitated from ethylacetate upon addition of hexanes and used without further purification.

Step D Preparation of2-(4′-piperidinopropoxy-2′-methylphenyl)-7-methylimidazo[1,2-a]pyridine

The product of Step C (200 mg) and piperidine (2.0 mL) were heated at100° C. for 2.5 hours. The reaction was cooled to ambient temperatureand partitioned between ethyl acetate (10 mL) and saturated sodiumbicarbonate solution (10 mL). The aqueous portion was extracted withadditional ethyl acetate (10 mL) and the organic portions combined,washed with brine, and evaporated. The residue was purified via silicagel chromatography (dichloromethane/methanol) to give the title compound(110 mg). ¹H-NMR (CD₃OD) δ 8.28 (d, J=7.0 Hz, 1H), 7.78 (s, 1H), 7.61(d, J=8.0 Hz, 1H), 7.31 (s, 1H), 6.84 (s, 1H), 6.79 (m, 2H), 4.04 (t,J=6.0 Hz, 2H), 2.50 (m, 12H), 1.99 (m, 2H), 1.64 (m, 4H), 1.51 (m, 2H).

EXAMPLE 23

A mixture of the product of Step C, Example 22 (360 mg) and4-piperidinopiperidine (195 mg) in acetone (5.5 mL) was treated withpotassium carbonate (165 mg). The mixture was stirred at 55° C.overnight and evaporated. The residue was partitioned between ethylacetate (25 mL) and saturated sodium bicarbonate solution (25 mL). Theaqueous portion was extracted with additional ethyl acetate (25 mL) anddichloromethane (25 mL) and the organic portions combined, washed withbrine, and evaporated. The residue was purified via silica gelchromatography (dichloromethane/2M ammonia in methanol) to give thetitle compound (150 mg). ¹H-NMR (CD₃OD) δ 8.21 (d, J=7.0 Hz, 1H), 7.75(s, 1H), 7.68 (m, 1H), 7.29 (s, 1H), 6.80 (m, 2H), 6.68 (m, 1H), 3.95(t, J=6.0 Hz, 2H), 2.94 (m, 2H), 2.44 (m, 9H), 2.37 (s, 3H), 2.14 (m,1H), 1.84 (m, 6H), 1.50 (m, 8H).

EXAMPLE 24

The product of Step C, Example 22 (300 mg) and hexamethyleneimine (2.0mL) were heated at 100° C. for 1.0 hour. The reaction was cooled toambient temperature and partitioned between ethyl acetate (10 mL) andsaturated sodium bicarbonate solution (10 mL). The aqueous portion wasextracted twice with additional ethyl acetate (10 mL) and the organicportions combined, washed with brine, and evaporated. The residue waspurified via silica gel chromatography (dichloromethane/methanol) togive the title compound (70 mg). ¹H-NMR (CDCl₃) δ 7.98 (d, J=7.0 Hz,1H), 7.83 (d, J=8.4 Hz, 1H), 7.54 (s, 1H), 7.37 (s, 1H), 6.83 (m, 2H),6.58 (dd, J=7.0 Hz, J=1.5 Hz, 1H), 4.05 (t, J=6.5 Hz, 2H), 2.67 (m, 6H),2.52 (s, 3H), 2.39 (s, 3H), 1.95 (m, 2H), 1.63 (m, 8H).

EXAMPLE 25

The product of Step C, Example 8 (160 mg) and 4-fluorobenzylamine (1.0mL) were heated at 100° C. for 40 minutes. The reaction was cooled toambient temperature and purified via silica gel chromatography(methanol/dichloromethane) to yield the title compound (16 mg) inapproximately 80% purity. ¹HNMR (CDCl₃): δ 7.97 (d, J=7.0 Hz, 1H), 7.85(m, 2H), 7.69 (s, 1H), 7.36 (br s, 1H), 7.28 (m, 2H), 6.96 (m, 4H), 6.59(dd, J=7.0 Hz, J=1.5Hz, 1H), 4.09 (t, J=6.0 Hz, 2H), 3.78 (s, 2H), 2.83(t, J=7.0 Hz, 2H), 2.39 (s, 3H), 2.00 (m, 2H).

EXAMPLE 26

Step A 3′-methoxy-4′-chloropropoxyacetophenone

A mixture of acetovanillone (10.0 g) and 1-bromo-3-chloropropane (8.3mL) in acetone (65 mL) was treated with potassium carbonate (13.3 g).The mixture was stirred at 52° C. for approximately 18 hours. Thereaction mixture was cooled to ambient temperature and filtered. Thefiltrate was evaporated and the residue partitioned betweendichloromethane (˜100 mL) and water (˜100 mL). The aqueous layer waswashed (2×) with a fresh portion of dichloromethane. The combinedorganic layers were washed with brine and evaporated to give the titlecompound which was used without further purification.

Step B Preparation ofalpha-bromo-3′-methoxy-4′-chloropropoxyacetophenone

A solution of the product of Step A (5.9 g) in ether (95 mL) was treatedwith bromine (1.3 mL) and the mixture stirred for approximately 60hours. The reaction mixture was slowly poured into saturated sodiumbicarbonate (100 mL) and then the organic layer was separated. Theaqueous layer was washed with a fresh portion of ether (100 mL). Thecombined ether layers were washed with water (100 mL), dried overmagnesium sulfate, filtered and evaporated. The residue was purified viasilica gel chromatography (hexanes/ethyl acetate) to yield the titlecompound (2.4 g).

Step C Preparation of2-(4′-chloropropoxy-3′-methoxyphenyl)-7-methylimidazo[1,2-a]pyridinehydrobromide

A solution of the product of Step B (1.44 g) and 2-amino-4-picoline(0.486 g) in ethanol (6 mL) was heated at 730° C. for 1 hour. Thereaction mixture was cooled to ambient temperature and evaporated to ayellow solid. The solid was stirred with 25 mL of dichloromethane forapproximately 10 minutes. The mixture was filtered and the solid productcollected to yield the title compound (1.3 g).

Step D Preparation of2-(4′-piperidinopropoxy-3′-methoxyphenyl)-7-methylimidazo[1,2-a]pyridine

The product of Step C (184 mg) and piperidine (1.5 mL) were heated at100° C. for 4 hours. The reaction was cooled to ambient temperature andpartitioned between ethyl acetate (10 mL) and saturated sodiumbicarbonate solution (10 mL). The aqueous portion was extracted twicewith additional ethyl acetate (10 mL) and once with dichloromethane (10mL). The organic portions were combined, washed with brine, andevaporated. The residue was purified via silica gel chromatography(dichloromethane/2M ammonia in methanol) to give the title compound (150mg). ¹H-NMR (CD₃OD) δ 8.17 (d, J=7.0 Hz, 1H), 7.93 (s, 1H), 7.50 (d,J=2.0 Hz, 1H), 7.38 (dd, J=8.0 Hz, J=2.0 Hz, 1H), 7.26 (s, 1H), 6.93 (d,J=8.0 Hz, 1H), 6.68 (dd, J=7.0 Hz, J=1.5 Hz, 1H), 4.00 (t, J=6.0 Hz,2H), 3.91 (s, 3H), 2.56 (m, 3H), 2.48 (br. s, 3 H), 2.38 (s, 3H), 1.98(m, 2H), 1.60 (m, 4H), 1.47 (m, 2H).

EXAMPLE 27

Step A Preparation of 2-(4′-nitrophenyl)-8-methylimidazo[1,2-a]pyridine

A mixture of 2-bromo-4′-nitroacetopheone (4.27 g) and 2-amino-3-picoline(1.9 g) in ethanol (20 mL) was stirred at reflux temperature for 1.5hours. The reaction mixture was cooled to ambient temperature andfiltered. The solid was collected and recrystallized (ethylacetate/methanol) to yield the title compound (2.2 g).

Step B Preparation of 2-(4′-aminophenyl)-8-methylimidazo[1,2-a]pyridine

A mixture of the product of Step A (1.48 g) and 1,4-cyclohexadiene (6.2mL) and palladium (10% wt on activated carbon) (1.4 g) in ethanol (100mL) was stirred at reflux temperature for 2 hours and cooled to ambienttemperature and stirred for 12 hours. The reaction mixture was filteredthrough a pad of celite and the celite pad rinsed with ethanol (100 mL)and methanol (100 mL). The filtrate was collected and evaporated toyield the title compound (710 mg).

Step C Preparation of2-[4′-[3-(Piperidinyl)]propanamidophenyl]-8-methylimidazo[1,2-a]pyridine

To a mixture of the product of Step B (330 mg) and N,N-diisopropylethylamine (0.28 mL) in dichloromethane (3 mL) and N,N-dimethylformamide(1 mL), was added 1-piperidinepropionic acid (256mg), WSC.HCl (1-Ethyl-3-(3′dimethylaminopropyl)-carbodiimide.HCl) (312mg), and 1-hydroxybenzotriazole hydrate (220 mg). The solution wasstirred at ambient temperature for approximately 18 hours. The mixturewas poured into a separatory funnel and washed sequentially with anequal volume of 1 N sodium hydroxide and water. The organic phase wasdried over sodium sulfate, decanted and evaporated. The residue waspurified via silica gel chromatography (methanol/dichloromethane) toyield the title compound (128 mg).

Step D Preparation of2-[4′-[3-(Pyrrolidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine

A mixture of the product of Step C (122 mg) and borane-methylsulfidecomplex (0.5 mL of a 2M solution in toluene) in toluene (3.5 mL) wasstirred and heated at reflux for 18 hours. The mixture was cooled toambient temperature and evaporated. The residue was treated with 1 M HCl(10 mL) and heated to reflux. The aqueous mixture was cooled to ambienttemperature and treated with solid sodium hydroxide until the pH of themixture was 8. The aqueous mixture was extracted three times withdichloromethane (10 mL each). The combined organic layers were driedover sodium sulfate, decanted and evaporated. The residue was purifiedvia silica gel chromatography (methanol/dichloromethane) to yield thetitle compound (60 mg). ¹H-NMR (CD₃OD) δ 8.16 (d, J=7.0 Hz, 1H), 7.90(s, 1H), 7.72 (m, 2H), 7.00 (m, 1H), 6.71 (m, 3H), 3.16 (t, J=7.0 Hz,2H), 2.59 (m, 9H), 1.86 (m, 2H), 1.65 (m, 4H), 1.50 (m, 2H).

EXAMPLE 28

This compound was prepared according to the procedures described StepsA-C, Example 27. ¹H NMR (CDCl₃) δ 7.98 (d, J=7.0 Hz, 1H), 7.92 (m, 2H),7.80 (s, 1H), 7.62 (m, 2H), 6.93 (m, 1H), 6.67 (t, J=7.0 Hz, 1H), 2.71(m, 3H), 2.65 (s, 3H), 2.57 (m, 5H), 1.75-1.50 (broad m, 6H).

EXAMPLE 29

The title compound was prepared according to the procedure of Example27, Step D from the corresponding amide (Example 6). ¹H NMR (400 MHz,CD₃OD) for HCl salt δ 8.59 (d, J=6.5 Hz, 1H), 8.34 (s, 1H), 7.75 (d,J=8.5 Hz, 2H), 7.71 (d, J=7.3 Hz, 1H), 7.37 (t, J=6.9 Hz, 1H), 6.91 (d,J=8.5 Hz, 2H), 3.36 (m, 2H), 3.26 (m, 6H), 2.70 (s, 3H), 2.08 (m, 2H),1.35 (t, J=7.3 Hz, 6H). MH⁺=337.2.

EXAMPLE 30

The title compound was prepared according to the procedure of Example27, Step D from the corresponding amide. ¹H NMR (400 MHz, CD₃OD) for HClsalt δ 8.61 (d, J=6.9 Hz, 1H), 8.33 (s, 1H), 7.70 (d, J=8.7 Hz, 2H),7.63 (s, 1H), 7.32 (dd, J=6.9 and 1.4 Hz, 1H), 6.94 (d, J=8.7 Hz, 2H),3.36 (m, 2H), 3.26 (q, J=7.3 Hz, 6H), 2.60 (s, 3H), 2.08 (m, 2H), 1.32(t, J=7.3 Hz, 6H). MH⁺=337.2.

EXAMPLE 31

The title compound was prepared according to the procedure of Example27, Step D from the corresponding amide (Example 28). ¹H NMR (400 MHz,CD₃OD) for HCl salt δ 8.58 (d, J=6.7 Hz, 1H), 8.33 (d, J=2.4 Hz, 1H),7.75 (d, J=8.7 Hz, 2H), 7.72 (d, J=7.3 Hz, 1H), 7.37 (t, J=7.0 Hz, 1H),6.90 (d, J=8.8 Hz, 2H), 3.64 (m, 4H), 3.36 (t, J=6.3 Hz, 2H), 3.03 (dt,J=2.9 and 12.3 Hz, 2H), 2.70 (s, 3H), 1.90 (m, 6H). MH⁺=335.1.

EXAMPLE 32

The title compound was prepared according to the procedure of Example27, Step D from the corresponding amide (Example 4). ¹H NMR (400 MHz,CD₃OD) for HCl salt δ 8.58 (d, J=6.7 Hz, 1H), 8.33 (d, J=5.6 Hz, 1H),7.76 (d, J=8.7 Hz, 2H), 7.72 (d, J=7.3 Hz, 1H), 7.37 (t, J=7.0 Hz, 1H),6.91 (d, J=8.7 Hz, 2H), 3.72 (m, 2H), 3.63 (t, J=6.0 Hz, 2H), 3.47 (t,J=6.0 Hz, 2H), 3.17 (m, 2H), 2.70 (s, 3H), 2.18 (m, 2H), 2.05 (m, 2H).MH⁺=321.

EXAMPLE 33

Step A Preparation of 2-[4-Bromophenyl]-7-methylimidazo[1,2-a]pyridine

A mixture of 2,4′-dibromoacetophenone (22.4 g) and 2-amino-4-picoline(8.68 g) in ethanol (80 mL) was heated at reflux temperature for 3hours. The reaction mixture was cooled to ambient temperature and thecrystalline solid isolated by filtration, washed with ethanol and driedin vacuo to give the title compound (13.1 g).

Step B Preparation of2-[4-[4-Hydroxybut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine

The product of Step A (1.8 g) in dry acetonitrile (40 mL) was treatedsequentially with tetrakis(triphenylphosphine)palladium(0) (0.1 g),triethylamine (1.27 g), and Cul (10 mg) then heated at 60° C. for 30minutes. The mixture was cooled to ambient temperature, treated with3-butyn-1-ol (0.361 g) and heated at reflux temperature for 18 hours.The mixture was cooled to ambient temperature and evaporated to dryness.The residue was crystallized, twice, from acetone to afford the titlecompound (1.02 g).

Step C Preparation of2-[4-[4-Methanesulfonyloxybut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine

The product of Step B (0.135 g) in dichloromethane (3 mL) was treatedwith pyridine (0.37 g) and cooled to 10° C. The cold solution wastreated with methanesulfonyl chloride (0.112 g) and allowed to stir andwarm to ambient temperature over 18 hours. The reaction mixture waswashed with 1% H₂SO₄ solution, saturated sodium bicarbonate solution,dried over magnesium sulfate, filtered and evaporated to give the titlecompound (0.115 g).

Step D Preparation of2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine

The product of Step C (1.00 g) in acetonitrile (15 mL) was treated withpiperidine (0.269 g) and potassium carbonate (1.17 g) and heated atreflux for 18 hours. The reaction mixture was cooled to ambienttemperature, washed with water (20 mL), dried over magnesium sulfate,filtered and evaporated to give crude product. Silica gel chromatography(methanol/dichloromethane) afforded the title compound (1.0 g). MS (ESI)m/z 344.1 (M+H⁺). ¹H NMR (DMSO) δ 8.23 (d, J=6.95 Hz, 1 H), 8.15 (s, 1H), 7.73 (d, J=8.37 Hz, 2 H), 7.25 (d, J=8.34 Hz, 2 H), 7.17 (s, 1 H),6.58 (dd, J=6.9,1.45 Hz, 1 H), 2.33 (m, 6 H), 2.23 (b, 2 H), 2.18 (s, 3H). 1.33 (pent, 4 H), 1.21 (pent, 2 H). HRMS: MH⁺ calcd for C₂₃H₂₆N₃,344.2127; found, 344.2134. Analysis: Calc'd for C₂₃H₂₅N₃; C, 80.43; H,7.34; N, 12.23. Found: C, 80.27; H, 7.15; N, 11.81.

EXAMPLE 34

The product of Step C, Example 33, (0.09 g) in acetonitrile (5 mL) wastreated with pyrrolidine (0.027 g) and potassium carbonate (0.105 g) andheated at reflux for 18 hours. The reaction mixture was cooled toambient temperature, diluted with ethyl acetate (20 mL), washed withwater (20 mL), dried over magnesium sulfate, filtered and evaporated togive crude product. Silica gel chromatography (methanol/dichloromethane)afforded the title compound (0.018 g). MS (ESI) m/z 330.1 (M+H⁺). ¹H NMR(CDCl₃) δ 7.92 (d, J=6.70 Hz, 1 H), 7.79 (d, J=8.28 Hz, 2 H), 7.71 (s, 1H), 7.38 (d, J=8.28 Hz, 2 H), 7.30 (s, 1 H), 6.54 (dd, J=6.89, 1.48 Hz,1 H), 2.72 (m, 2 H), 2.61 (m, 6 H), 2.33 (s, 3 H). 1.76 (m, 4 H). HRMS:MH⁺ calcd for C₂₂H₂₄N₃, 330.1970; found, 330.1976.

EXAMPLE 35

The product of Step C, Example 33, (0.09 g) in acetonitrile (5 mL) wastreated with cycloheptylamine (0.038 g) and potassium carbonate (0.105g) and heated at reflux for 18 hours. The reaction mixture was cooled toambient temperature, diluted with ethyl acetate (20 mL), washed withwater (20 mL), dried over magnesium sulfate, filtered and evaporated togive crude product. Silica gel chromatography (methanol/dichloromethane)afforded the title compound (0.024 g). MS (ESI) m/z 358.1 (M+H⁺). ¹H NMR(CDCl₃) δ 7.92 (d, J=6.89 Hz, 1 H), 7.79 (d, J=8.30 Hz, 2 H), 7.70 (s, 1H), 7.32 (d, J=8.28 Hz, 2 H), 7.30 (s, 1 H), 6.54 (dd, J=6.88, 1.42 Hz,1 H), 2.81 (m, 2 H), 2.70 (mb, 4 H), 2.55 (t, J=7.5 Hz, 2 H). 2.33 (s, 3H), 1.55 (m, 8 H), HRMS: MH⁺ calcd for C₂₄H₂₈N₃, 358.2283; found,358.2265. Analysis: Calc'd for C₂₄H₂₇N₃ 0.6CH₂Cl₂; C, 71.54; H, 6.90; N,10.15. Found: C, 71.19; H, 6.76; N, 9.97.

EXAMPLE 36

Step A Preparation of 4-Piperidinylbut-1-ene

4-Bromobut-1-ene (1.35 g) was treated with piperidine (1.7 g) and heatedat reflux for 3 hours. The mixture was cooled to ambient temperature,filtered and the residue washed with ether (50 mL). The combinedfiltrate and washings were evaporated to give the title compound (1.3g).

Step B(E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine

The product of Step A (0.76 g) was combined with the product of Example33, Step A (1.21 g) and treated with triethylamine (74 mL),palladium(II)acetate (0.095 g), triphenylphosphine (0.221 g) andN,N-dimethylformamide (5 mL). The mixture was heated at reflux for 24hours and cooled to ambient temperature. The reaction mixture wasfiltered and the residue washed with ethyl acetate (150 mL). Thefiltrate and washings were combined, washed with water (2×200 mL), driedover sodium sulfate, filtered and evaporated to give crude product. Thecrude product was purified via silica gel chromatography(ethanol/dichloromethane) to give the title compound (0.8 g). MS (ESI)m/z 346.1 (M+H⁺). ¹H NMR (CDCl₃) δ 7.91 (d, J=4.4 Hz, 1 H), 7.83-7.77(m, 2 H), 7.71 and 7.69 (s, 1 H E/Z), 7.34-7.29 (m, 3 H), 6.53-6.51 (m,1 H), 6.40 (dd, J=16.00, 9.20 Hz, 1 H E/Z), 6.22-6.13 (m, 1 H) 2.44-2.39(m, 6 H), 2.32 (s, 3 H), 1.80-1.38 (m, 8 H), HRMS: MH⁺ calcd forC₂₃H₂₈N₃, 346.2283; found, 346.2274. Analysis: Calc'd for C₂₃H₂₇N₃; C,79.96; H, 7.88; N, 12.16. Found: C, 79.90; H, 7.77; N, 11.79.

EXAMPLE 37

Step A Preparation of2-[4-[4-Hydroxybutyl]phenyl]-7-methylimidazo[1,2-a]pyridine

The product of Step B, Example 33 (0.3 g) in ethanol (15 mL) washydrogenated over 5% palladium on barium sulfate (0.06 g) for 4.5 hours.The reaction mixture was filtered and evaporated to afford the titlecompound (0.282 g).

Step B Preparation of2-[4-[4-Methanesulfonyloxybutyl]phenyl]-7-methylimidazo[1,2-a]pyridine

The product of Step A (0.33 g) in dichloromethane (20 mL) was treatedwith triethylamine ( 0.36 g) and cooled to 0° C. The cold solution wastreated with methanesulfonyl chloride (0.338 g) and allowed to stir andwarm to ambient temperature over 18 hours. The reaction mixture waswashed with water (50 mL), saturated sodium bicarbonate solution (25mL), water (50 mL), dried over sodium sulfate, filtered and evaporatedto give the crude title compound (0.53 g). The crude product was used,Step C, without further purification.

Step C Preparation of2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine

The crude product from Step B (0.14 g) in acetonitrile (10 mL) wastreated with pyrrolidine (0.056 g) and potassium carbonate (0.162 g) andheated at reflux for 18 hours. The reaction mixture was cooled toambient temperature, diluted with ethyl acetate (100 mL), washed withwater (50 mL), dried over magnesium sulfate, filtered and evaporated togive crude product. Silica gel chromatography(methanol/dichloromethane/ammonia) afforded the title compound (0.054g). MS (ESI) m/z 334.1 (M+H⁺). ¹H NMR (CDCl₃) δ 8.13 (d, J=6.93 Hz, 1H), 7.99 (d, J=8.20 Hz, 2 H), 7.89 (s, 1 H), 7.52 (s, 1 H), 7.39 (d,J=8.2 Hz, 2 H), 6.74 (dd, J=6.89, 1.57 Hz, 1 H), 2.81 (m, 2 H), 2.65 (m,6 H). 2.54 (s, 3 H), 1.95-1.71 (m, 8 H), HRMS: MH⁺ calcd for C₂₂H₂₈N₃,334.2283; found, 334.2281. Analysis: Calc'd for C₂₂H₂₇N₃ H₂O; C, 75.18;H, 8.32; N, 11.96. Found: C, 74.90; H, 8.18; N, 11.77.

EXAMPLE 38

Step A

2-amino-4-picoline (8.68 g, 80.266 mmol) and 2,4′-dibromoacetophenone(22.4 g, 80.59 mmol) were dissolved into absolute ethanol (80 mL). Theresulting solution was allowed to reflux under nitrogen for 3 h. Thereaction mixture was cooled and filtered to yield solid crude 16.8 g(72.7%). Crude product was crystallized with boiling ethanol (100 mL) toyield 13.3 g (57.5%) as a pure white crystalline solid.

Step B

A mixture of bromo product from step A (720.4 mg, 2.5 mmol),3-butyn-1-ol (361 mg, 5 mmol), cuprous iodide (10 mg, 0.052 mmol),triethylamine (1.743 mL, 12.5 mmol), tetrakis (triphenylphosphine)Pd(0)(100 mg, 0.087 mmol) was refluxed in anh. acetonitrile (40 mL) for 18 h.Cooled to room temperature and evaporated to dryness to yield 1.745 gcrude yellow solid. The crude was purified by silica-gel columnchromatography using 2M ammonia in methanol: dichloromethane (7:93) as asolvent system. The yield of the pure alkyl alcohol was 390 mg (56.5%),a light yellow solid.

Step C

To a solution of alkyl alcohol from step B (300 mg, 1.09 mmol) intoethanol (15 mL) was added 5% Pd/BaSO₄ (50 mg). The mixture washydrogenated at ambient condition for 4½ h. under stirring. Filtered andevaporated to dryness to yield almost pure saturated alcohol (257 mg,100%).

Step D

To a cooled solution at 5° C. of alcohol from step C (330 mg, 1.18 mmol)and triethylamine (360 mg, 3.54 mmol) in dichloromethane (20 mL) wasadded slowly methanesulfonyl chloride (338 mg, 3.00 mmol). Reactionmixture was allowed to stir overnight at room temperature under nitrogenatmosphere. Then reaction mixture was diluted to 60 mL with moredichloromethane and washed successively with cold 5% NaHCO₃ (aq) (2×25mL) and cold water (2×20 mL). Organic phase was dried over anhydrousNa₂SO₄, filtered and evaporated to dryness to yield almost pure mesylatein quantitative yield.

Step E

A mixture of mesylate (140 mg, 0.39 mmol) from step D, piperidine (66.5mg, 0.78 mmol) and anhydrous K₂CO₃ (162 mg, 1.17 mmol) in anhydrousacetonitrile (10 mL) was refluxed overnight under nitrogen atmosphere.Then the reaction mixture was cooled to room temperature and partitionedbetween dichloromethane and water. Separated organic phase was driedover Na₂SO₄, filtered and evaporated to dryness to yield 233 mg crudeproduct. Crude product was purified on silica gel column using 2Mammonia in methanol: dichloromethane (7:93) as a solvent system to yield65 mg (48%) final pure product. MS (ESI) m/z 348.1 (M+H⁺). ¹H NMR(CDCl₃) δ 7.91 (d, J=7.33 Hz, 1 H), 7.77 (d, J=8.59 Hz, 2 H), 7.67 (s, 1H), 7.30 (s, 1 H), 7.16 (d, J=8.08 Hz, 2 H), 6.52 (dd, J=7.07, 2.02 Hz,1 H), 2.58 (t, J=7.83 Hz, 2 H), 2.28 (m, 8 H), 1.52 (m, 11 H). HRMS: MH⁺calcd for C₂₃H₃₀N₃, 348.2440; found, 348.2455. Analysis: Calc'd forC₂₃H₂₉N₃; C, 79.5; H, 8.41; N, 12.09. Found: C, 79.18; H, 8.47; N,11.90.

EXAMPLE 39

A mixture of mesylate (Example 1, Step D) (140 mg, 0.39 mmol) from stepD, hexamethyleneimine (77.4 mg, 0.78 mmol) and anhydrous K₂CO₃ (162 mg,1.17 mmol) in anhydrous acetonitrile (10 mL) was refluxed overnightunder nitrogen atmosphere. Then the reaction mixture was cooled to roomtemperature and partitioned between dichloromethane and water. Separatedorganic phase was dried over Na₂SO₄, filtered and evaporated to drynessto yield 190 mg crude product. Crude product was purified on silica gelcolumn using 2M ammonia in methanol:dichloromethane (7:93) as a solventsystem to yield 52 mg (37%) final pure product. MS (ESI) m/z 362.3(M+H). ¹H NMR (CDCl₃) δ 7.89 (d, J=6.84 Hz, 1 H), 7.76 (d, J=8.2 Hz, 2H), 7.66 (s, 1 H), 7.29 (s, 1 H), 7.15 (d, J=8.16, 2 H), 6.51 (dd,J=6.88,1.52 Hz, 1 H), 2.59 (m, 6 H), 2.47 (t, J=7.68 Hz, 2 H), 2.32 (s,3 H), 1.57 (m, 12 H). HRMS: MH⁺ calcd for C₂₄H₃₂N₃, 362.2596; Found,362.2589. Analysis: Calc'd for C₂₄H₃₁N₃ 0.25 H₂O; C, 78.74; H, 8.56; N,11.60. Found: C, 78.83; H, 8.59; N, 11.43.

EXAMPLE 40

Step A

A mixture of bromo product from Example 38, Step A (2.872 g, 10 mmol),3-butene-1-ol (0.938 g, 13 mmol), Pd(OAc)₂ (224.5 mg, 1 mmol) andtriphenylphosphine (525 mg, 2 mmol) was dissolved into triethylamine(12.65 g, 125 mmol) under nitrogen atmosphere and refluxed for 24 h. Thereaction mixture was cooled to room temperature and diluted with ethylacetate (100 mL). The resulting solution was washed with water (2×30mL). Dried over anhydrous Na₂SO₄, filtered and evaporated to dryness toyield 2.5 g brownish yellow crude product. Crude product was purified onsilica gel column using acetone:dichloromethne (2:8) yielding 0.60 g(18.1%) pure product.

Step B

To a cooled solution at 5° C. of butenol from step B (580 mg, 2.083mmol) and triethylamine (632.5 mg, 6.25 mmol) in dichloromethane (40 mL)was added slowly methanesulfonyl chloride (716 mg, 6.25 mmol). Reactionmixture was allowed to stir overnight at room temperature under nitrogenatmosphere. Then reaction mixture was diluted to 100 mL with moredichloromethane and washed successively with cold 5% NaHCO₃ (aq) (2×30mL) and cold water (2×30 mL). Organic phase was dried over anhydrousNa₂SO₄, filtered and evaporated to dryness to yield almost pure mesylatein quantitative yield.

Step C

A mixture of mesylate (120 mg, 0.35 mmol) from step C, pyrrolidine (74.7mg, 1.05 mmol) and anhydrous K₂CO₃ (146 mg, 1.05 mmol) in anhydrousacetonitrile (10 mL) was refluxed 3 h. under nitrogen atmosphere. Thenthe reaction mixture was cooled to room temperature and partitionedbetween dichloromethane and water. Separated organic phase was driedover Na₂SO₄, filtered and evaporated to dryness to yield 80 mg crudeproduct. Crude product was purified on silica gel column using 2 Mammonia in methanol: dichloromethane (5:95) as a solvent system to yield47 mg (14.2%) final pure product. MS (ESI) m/z 332.1 (M+H⁺). ¹H NMR(CDCl₃) δ 7.91 (d, J=6.84 Hz, 1 H), 7.8 (d, J=8.29 Hz, 2 H), 7.69 (s, 1H), 7.33 (d, J=8.28 Hz, 2 H), 7.28 (s, 1 H), 6.53 (dd, J=6.88 Hz, 1.52Hz, 1 H), 6.4 (d, J=15.84 Hz, 1 H), 6.2 (dt, J=15.76, 6.88, 1 H),2.74-2.32 (m, 15 H). HRMS: MH⁺ calcd for C₂₂H₂₆N₃ 332.2127; found,332.2119. Analysis: Calc'd for C₂₂H₂₅N₃ H₂O; C, 75.61; H, 7.79; N,12.02. Found: C, 75.77; H, 7.07; N, 11.87.

EXAMPLE 41

Step A

A mixture of 1-bromo-3-butene (1.35 g, 10 mmol) and piperidine (1.70 g,20 mmol) neat was refluxed under nitrogen atmosphere for 3 h. Cooled toRT, filtered and dissolved into ethyl ether (40 mL). Then solution waswashed with water (2×30 mL) and dried over anhydrous Na₂SO₄, filteredand evaporated to dryness to yield 1.3 g (74.15%) oily1-piperidyl-3-butene.

Step B

A mixture of bromo product from (Example 38, Step A) (1.21 g, 4.2 mmol),1-piperidyl-3-butene from Step A above (0.760 g, 5.46 mmol),palladium(II) acetate (95 mg, 0.42 mmol) and triphenylphosphine (221 mg,0.84 mmol) was dissolved in triethylamine (53.2 g, 52.5 mmol) undernitrogen atmosphere. Dimethyl formamide (5 mL) was added to dissolve allingredients and refluxed for 24 h. The reaction mixture was cooled toroom temperature and diluted with ethyl acetate (150 mL). Filtered thesolution to remove solid suspension. The filtrate was washed with water(2×200 mL). Dried over anhydrous Na₂SO₄, filtered and evaporated todryness to yield 1.4 g brownish yellow crude product. Crude product waspurified on silica gel column using ethanol: dichloromethane (5:95)yielding 0.80 g (55.2%) pure product.

Step C

Olefin from Step B above (100 mg, 0.29 mmol) was dissolved into methanol(20 mL) and added platinum(IV)oxide (20 mg). The resulting mixture washydrogenated in Parr bottle at 50 psi hydrogen pressure for 32 h.Reaction mixture was filtered and evaporated to dryness to yield 60 mg(59%) of the final product. MS (ESI) m/z 352.1 (M+H⁺). ¹H NMR (CD₃OD) δ7.75 (s, 1 H), 7.63 (d, J=7.5 Hz, 2 H), 7.39 (d, J=7.5 Hz, 2 H), 4.2 (m,2 H), 3.6-1.5 (m, 23 H), 1.23 (d, J=6.06 Hz, 3 H). HRMS: MH⁺ calcd forC₂₃H₃₄N₃, 352.2753; found, 352.2749. Analysis: Calc'd for C₂₃H₃₃N₃; C,78.58; H, 9.46; N, 11.95. Found: C, 63.66; H, 9.18; N, 7.70.

EXAMPLE 42

This compound was prepared according to the procedure described inExample 1 of U.S. Pat. No. 4,727,145. using2-(4-chloropropoxyphenyl)-8-methylimidazo[1,2-a]pyridine andalpha-methylbenzylamine instead of2-(4-chloropropoxyphenyl)-imidazo[1,2-a]pyridine and dibutylaminerespectively.

Analysis: Calc'd for C₂₅H₂₇N₃O 3HCl; C, 6.11; H, 60.8; N, 8.49. Found:C, 6.51; H, 60.43; N, 8.36.

EXAMPLE 43

This compound was prepared according to the procedure described inExample 1 of U.S. Pat. No. 4,727,145. using2-(4-chloropropoxyphenyl)-8-methylimidazo[1,2-a]pyridine and anilineinstead of 2-(4-chloropropoxyphenyl)-imidazo[1,2-a]pyridine anddibutylamine respectively.

Analysis: Calc'd for C₂₄H₂₅N₃O 3HCl; C, 5.87; H, 59.95; N, 8.74. Found:C, 5.7; H, 59.81; N, 8.59.

EXAMPLE 44

This compound was prepared according to the procedure described inExample 1 of U.S. Pat. No. 4,727,145. using2-(4-chloropropoxyphenyl)-8-methylimidazo[1,2-a]pyridine and4-amino-N-benzylpiperidine instead of2-(4-chloropropoxyphenyl)-imidazo[1,2-a]pyridine and dibutylaminerespectively.

EXAMPLE 45

This compound was prepared according to the procedure described inExample 1 of U.S. Pat. No. 4,727,145. using2-(4-chloropropoxyphenyl)-8-methylimidazo[1,2-a]pyridine andN-phenethylpiperazine instead of2-(4-chloropropoxyphenyl)-imidazo[1,2-a]pyridine and dibutylaminerespectively.

EXAMPLE 46

Step A Preparation of alpha bromo-4-hydroxyacetophenone

4-Acetylphenol (20 g) in ether (200 mL) was treated with bromine (6.8mL) and stirred at ambient temperature for 18 hours. The solution waspoured into saturated sodium bicarbonate, stirred for 30 minutes and theorganic layer separated. The organic portion was washed with saturatedsodium bicarbonate, dried over magnesium sulfate, filtered andevaporated to afford the title compound (30 g).

Step B Preparation of 2-[4-hydroxyphenyl]-8-methylimidazo[1,2-a]pyridine

The product of step A (30 g) and 2-aminopicoline (15 mL) in ethanol (200mL) was heated at reflux temperature for 4 hours then cooled to ambienttemperature. The resulting precipitate containing the title compound wasisolated via filtration (27 g).

Step C Preparation of2-[4-[(2,3-Epoxy)propoxy]phenyl]-8-methylimidazo[1,2-a]pyridine

The product of Step B (27 g) in methanol (500 mL) was treated withpotassium hydroxide (14 g) and stirred at ambient temperature for 2hours. To this solution was then added epichlorohydrin (9.4 mL) and themixture stirred for an additional 48 hours. The reaction mixture wasdiluted with dichloromethane, filtered and the filtrate washed withwater, dried, sodium sulfate filtered and evaporated to afford the titlecompound (18.2 g).

Step D Preparation of2-[4-(2-hydroxy-3-propylaminopropoxy)phenyl]-8-methylimidazo[1,2-a]pyridine

The product of Step C (5.0 g) and propylamine (20 mL) was heated at 40°C. for 18 hours. The reaction was cooled to ambient temperatureevaporated and the residue purified via silica gel chromatography(dichloromethane/methanol) to give the title compound which wasconverted to a HCl salt upon treatment with HCl/methanol.

Analysis: Calc'd for C₂₀H₂₅N₃O₂ HCl H₂O; C, 7.16; H, 60.98; N, 10.67.Found: C, 7.31; H, 60.86; N, 10.92.

EXAMPLE 47

The title compound was prepared by reacting the product of Step C,Example 25 with dibutylamine.

Analysis: Calc'd for C₂₃H₃₁N₃O₂ 2HCl; C, 7.32; H, 60.79; N, 9.25. Found:C, 6.95; H, 0.81; N, 9.06.

EXAMPLE 48

The title compound was prepared by reacting the product of Step C,Example 25 with dipropylamine.

Analysis: Calc'd for C₂₅H₃₅N₃O₂ 2HCl; C, 7.73; H, 62.23; N, 8.71. Found:C, 7.82; H, 62.05; N, 8.47.

EXAMPLE 49

The title compound was prepared by reacting the product of Step C,Example 25 with 1,1-dimethylethylamine.

Analysis: Calc'd for C₂₁H₂₇N₃O₂ 2HCl; C, 6.86; H, 59.16; N, 9.85. Found:C, 6.66; H, 59.04; N, 9.74.

EXAMPLE 50

2-[4-[(3-Chloro-2-hydroxy)propoxy]phenyl]-8-methylimidazo[1,2-a]pyridine(5.0 g) in ethanol (10 mL) and N-phenethylpiperazine (1.4 g) were heatedat 60° C. for 18 hours. The reaction mixture was cooled to ambienttemperature, evaporated and purified via silica gel chromatography(dichloromethane/methanol) to give the title compound which wasconverted to a hydrochloride salt upon treatment with HCl/methanol. M.p.225-228° C.

EXAMPLE 51

2-[4-[(3-Chloro-2-hydroxy)propoxy]phenyl]-8-methylimidazo[1,2-a]pyridine(5.0 g) in ethanol (10 mL) and N-benzyl-4-aminopiperidine (1.4 g) wereheated at 60° C. for 18 hours. The reaction mixture was cooled toambient temperature, evaporated and purified via silica gelchromatography (dichloromethane/methanol) to give the title compoundwhich was converted to a hydrochloride salt upon treatment withHCl/methanol.

EXAMPLE 52

The product of Example 16 Step A (60 mg) and piperidine (1.0 mL) wereheated at 100° C. for 1.5 hours. The reaction was cooled to ambienttemperature and partitioned between ethyl acetate (10 mL) and saturatedsodium bicarbonate solution (10 mL). The aqueous portion was extractedwith a fresh portion of ethyl acetate (10 mL) and the organic portionscombined and washed with brine (10 mL). The organic portions were driedover magnesium sulfate, filtered and evaporated. The residue waspurified via silica gel chromatography (dichloromethane/methanol) togive the title compound (60 mg). ¹H-NMR (CD₃OD) δ8.30 (m, 1H), 8.00 (s,1H), 7.74 (m, 2H), 7.43 (m, 1H), 7.20 (m, 1H), 6.90 (m, 2H), 6.80 (m,1H), 3.98 (t, J=6.0 Hz, 2H), 2.47 (m, 6H), 1.93 (m, 2H), 1.55 (m, 4H),1.41 (m, 2H).

EXAMPLE 53

Step A Preparation of 3-Chloro-propane-1-sulfonic acid[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide

To a suspension of the product of Example 27 Step B (195 mg) inN,N-dimethylformamide (2 mL) was added triethylamine (0.12 mL) and themixture cooled to 0° C. 3-chloropropanesulfonyl chloride (0.11 mL) wasadded dropwise and the mixture stirred for 1.5 hours before the additionof H₂O (2 mL). The reaction mixture was partitioned between H₂O (15 mL)and ethyl acetate (15 mL). The aqueous layer was brought to pH=9-10 withsaturated sodium bicarbonate solution and extracted with ethyl acetate(2×). The combined organic layers were dried over magnesium sulfate,decanted, and evaporated. The residue was purified via silica gelchromatography (dichloromethane/methanol) to give the title compound(210 mg).

Step B Preparation of 3-Piperidin-1-yl-propane-1-sulfonic acid[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide

The product of Step A (65 mg) and piperidine (1.0 mL) were heated at100° C. for 1.5 hours. The reaction was cooled to ambient temperatureand partitioned between ethyl acetate (15 mL) and saturated sodiumbicarbonate solution (15 mL). The aqueous portion was extracted with afresh portion of ethyl acetate (15 mL) (2×) and the organic portionscombined and washed with brine (15 mL). The organic portions were driedover magnesium sulfate, filtered and evaporated. The residue waspurified via silica gel chromatography (dichloromethane/methanol) togive the title compound (26 mg). ). ¹H-NMR (CD₃OD) δ ¹H-NMR (CD₃OD) δ8.14 (d, J=7.0 Hz, 1H), 8.00 (s, 1H), 7.81 (m, 2H), 7.23 (m, 2H), 6.98(m, 1H), 6.70 (t, J=7.0 Hz, 1H), 3.07 (m, 2H), 2.49 (s, 3H), 2.31 (m,6H), 1.87 (m, 2H), 1.44 (m, 4H), 1.33 (m, 2H).

EXAMPLE 54

This compound was prepared according to the procedure described inExample 1 of U.S. Pat. No. 4,727,145 or J. Med. Chem. 188, 31, 2221 etseq., above using2-(4-chloropropoxyphenyl)-8-methylimidazo[1,2-a]pyridine and piperidineinstead of 2-(4-chloropropoxyphenyl)-imidazo[1,2-a]pyridine anddibutylamine respectively. Analysis: Calc'd for C₂₂H₂₇N₃O 3HCl 1H₂O; C,6.76; H, 55.41; N, 8.81. Found: C, 6.63; H, 55.02; N, 8.55.

EXAMPLE 55

2-(4-Morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine K_(i)=25 nM

This compound was prepared according to the procedure described inExample 1 of U.S. Pat. No. 4,727,145 or J. Med. Chem. 188, 31, 2221 etseq., using 2-(4-chloropropoxyphenyl)-8-methylimidazo[1,2-a]pyridine andmorpholine instead of 2-(4-chloropropoxyphenyl)-imidazo[1,2-a]pyridineand dibutylamine respectively. Analysis: Calc'd for C₂₁H₂₅N₃O₂ 3HCl1.0H₂O; C, 6.31; H, 52.67; N, 8.78. Found: C, 6.69; H, 52.87; N, 8.89.

F. Biological Examples

In the present invention receptor binding was determined using the humanhistamine H₃ receptor (See Lovenberg et al Mol. Pharmacol. 1999, 1107).Screening using the human receptor is particularly important for theidentification of new therapies for the treatment of human disease.Conventional binding assays for example are determined using ratsynaptosomes (Garbarg et al J. Pharmacol. Exp. Ther. 1992, 263, 304),rat cortical membranes (West et al Mol. Pharmacol. 1990, 610), andguinea pig brain (Korte et al Biochem. Biophys. Res. Commun. 1990, 978).Only limited studies have been performed previously using human tissuebut these allude to significant differences in the pharmacology ofrodent and primate receptors (West et al Eur. J. Pharmacol. 1999, 233).

Biological Example 1

1(A) Transfection of Cells with Human Histamine Receptor

A 10 cm tissue culture dish with a confluent monolayer of SK-N-MC cellswas split two days prior to transfection. Using sterile technique themedia was removed and the cells were detached from the dish by theaddition of trypsin. One fifth of the cells were then placed onto a new10 cm dish. Cells were grown in a 37° C. incubator with 5% CO₂ inMinimal Essential Media Eagle with 10% Fetal Bovine Serum. After twodays cells were approximately 80% confluent. These were removed from thedish with trypsin and pelleted in a clinical centrifuge. The pellet wasthen re-suspended in 400 μL complete media and transferred to anelectroporation cuvette with a 0.4 cm gap between the electrodes(Bio-Rad #165-2088). One microgram supercoiled H₃ receptor cDNA wasadded to the cells and mixed. The voltage for the electroporation wasset at 0.25 kV, the capacitance is set at 960 μF.

After electroporation the cells were diluted into 10 mL complete mediaand plated onto four 10 cm dishes. Due to the variability in theefficiency of electroporation, four different concentrations of cellswere plated. The ratios used were: 1:20, 1:10, and 1:5, with theremainder of the cells being added to the fourth dish. The cells wereallowed to recover for 24 hours before adding the selection media(complete media with 600 μg/ml G418). After 10 days dishes were analyzedfor surviving colonies of cells. Dishes with well-isolated colonies wereused. Cells from individual colonies were isolated and tested. SK-N-MCcells were used because they give efficient coupling for inhibition ofadenylate cyclase. The clones that gave the most robust inhibition ofadenylate cyclase in response to histamine were used for further study.

1(B) [³H]-N-methylhistamine binding

Cell pellets from histamine H₃ receptor-expressing SK-N-MC cells werehomogenized in 20 mM TrisHCl/0.5 mM EDTA. Supernatants from a 800 g spinwere collected, reccentrifuged at 30,000 g for 30 minutes. Pellets wererehomogenized in 50 mM Tris/5 mM EDTA (pH 7.4). Membranes were incubatedwith 0.8 nM [³H]-N-methylhistamine plus/minus test compounds for 45minutes at 25° C. and harvested by rapid filtration over GF/C glassfiber filters (pretreated with 0.3% polyethylenimine) followed by fourwashes with ice cold buffer. Filters were dried, added to 4 mLscintillation cocktail and then counted on a liquid scintillationcounter. Non-specific binding was defined with 10 μM histamine accordingto Chen and Prusoff, Biochem. Pharmacol. 1973, 22:3099. K_(I) valueswere calculated based on a K_(D) of 800 pM and a ligand concentration([L]) of 800 pM according to the formula:K_(I)=(IC₅₀)/(1+([L]/(K_(D))). K_(I) values are provided in the examplesabove.F. Other Embodiments

The features and advantages of the invention are apparent to one ofordinary skill in the art. Based on this disclosure, including thesummary, detailed description, background, examples, and claims, one ofordinary skill in the art will be able to make modifications andadaptations to various conditions and usages. These other embodimentsare also within the scope of the invention.

1. A compound of formula (I)(A):

wherein both dashed lines complete a carbon-carbon double bond, or bothare absent; R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl; each of R₅, R₆, R₇and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino; oneof R_(a), R_(b), R_(c), R_(d), and R_(e) is —WYZ and the others areindependently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;W is NR₁₀, —(CO)(O)R₉, —N(R₁₀)SO₂—R₉, —O(CO)R₉, —(CO)NR₁₀, or—N(R₁₀)—CO—R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R₁₀ isH, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclicradical; Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆alkoxy; Z is C₂₋₈ heterocyclic radical with at least one basic nitrogenatom in the ring, optionally including in the ring up to 3 additionalheteroatoms or moieties independently selected from O, C═O, N, NH, NG,S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅;and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, orC₄₋₇ cycloalkenyl; and each of the above hydrocarbyl or heterocyclicgroups being optionally substituted with between 1 and 3 substituentsselected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical,phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the aboveheterocyclic groups may be attached to the rest of the molecule by acarbon atom or a heteroatom; or a pharmaceutically acceptable salt,amide, ester, or hydrate thereof.
 2. A compound of claim 1, wherein Zcomprises piperidyl, morpholinyl, piperazinyl or pyrrolidyl. 3.(canceled)
 4. A compound of claim 1, wherein W is C₂₋₄ alkylamino.
 5. Acompound of claim 1, wherein W comprises propylamino, or ethylamino; andone of R₇ and R₈ is methyl.
 6. A compound of claim 1, where R₇ ismethyl.
 7. A compound of claim 1 wherein at least one of R_(a), R_(b),R_(d), and R_(e) is methyl.
 8. A compound of claim 1, wherein each ofR₅, R₆, R₇ and R₈is independently H, methyl, ethyl, methoxy, ethoxy,fluoro, or chloro; or wherein one of R_(a), R_(b), R_(c), R_(d), andR_(e) is WZ and the others are independently selected from H, methyl,ethyl, methoxy, ethoxy, fluoro, or chloro.
 9. A compound of claim 1,wherein both dashed lines are present to form two carbon-carbon doublebonds.
 10. A compound of claim 1, wherein both dashed lines are absent.11. A compound of claim 1, wherein R_(a) or R_(e) is methyl, fluoro, ormethoxy.
 12. (canceled)
 13. (canceled)
 14. A compound of claim 1,wherein R₃ is H or methyl; each of R_(b) and R_(d) is independently H,methyl, or methoxy; each of R₇ and R₈ is independently H, methyl,fluoro, or chloro; each of R₅ and R₆ is H; each of R_(a) or R_(e) isindependently H, methyl, fluoro, or chloro; W is N(R₁₀)SO₂—(C₁₋₅ alkyl),—(CO)O—C₂₋₃ alkyl, —(CO)NH—(C₁₋₃ alkyl), —NH(CO)(C₁₋₃ alkyl), or—NH(C₁₋₆ alkyl); and Z is pyrrolidyl, piperidyl, morpholinyl,piperazinyl, (piperidyl)-piperidyl.
 15. (canceled)
 16. (canceled) 17.(canceled)
 18. (canceled)
 19. A pharmaceutical composition comprising acompound of claim 1, formula (I) and a pharmaceutically-acceptablecarrier.
 20. A pharmaceutical composition of claim 19, wherein saidcompound has a formula wherein R₃ is H or methyl; each of R_(b) andR_(d) is independently H, methyl, or methoxy; each of R₇ and R₈ isindependently H, methyl, fluoro, or chloro; each of R₅ and R₆ is H; eachof R_(a) or R_(e) is independently H, methyl, fluoro, or chloro; W is—(CO)O—C₂₋₃ alkyl, —N(R₁₀)SO₂—R₉, —(CO)NH—(C₁₋₃ alkyl), —NH(CO)(C₁₋₃alkyl), or NH(C₁₋₆ alkyl); and Z is pyrrolidyl, piperidyl, morpholinyl,piperazinyl, or (piperidyl)-piperidyl.
 21. (canceled)
 22. (canceled) 23.A method for treating disorders mediated by the histamine H₃ receptor ina patient, said method comprising administering to the patient apharmaceutically effective amount of compound of formula (I):

wherein both dashed lines complete a carbon-carbon double bond, or bothare absent; R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl; each of R₅, R₆, R₇and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino; oneof R_(a), R_(b), R_(c), R_(d), and R_(e) is —WYZ and the others areindependently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;W is NR₁₀, —(CO)(O)R₉, —N(R₁₀)SO₂—R₉, —O(CO)R₉, —(CO)NR₁₀, or—N(R₁₀)—CO—R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R₁₀ isH, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclicradical; Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆alkoxy; Z is C₂₋₈ heterocyclic radical with at least one basic nitrogenatom in the ring, optionally including in the ring up to 3 additionalheteroatoms or moieties independently selected from O, C═O, N, NH, NG,S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅;and each of the above hydrocarbyl or heterocyclic groups beingoptionally substituted with between 1 and 3 substituents selected fromC₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical, phenyl, andphenyl(C₁₋₃ alkyl); and wherein each of the above heterocyclic groupsmay be attached to the rest of the molecule by a carbon atom or aheteroatom; or a pharmaceutically acceptable salt, amide, ester, orhydrate thereof.
 24. (canceled)
 25. (canceled)
 26. A method for treatinga patient with a central nervous system disorder, selected fromsleep/wake disorders, arousal/vigilance disorders, dementia, Alzheimer'sdisease, epilepsy, narcolepsy, eating disorders, motion sickness,vertigo, attention deficit hyperactivity disorder, learning and memorydisorders, mild cognitive impairment, schizophrenia, allergic rhinitisand asthma said method comprising administering to the patient apharmaceutically-effective amount of a compound of formula (I):

wherein both dashed lines are complete a carbon-carbon double bond, orboth are absent; R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl; each of R₅, R₆,R₇ and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino;one of R_(a), R_(b), R_(c), R_(d), and R_(e) is —WYZ and the others areindependently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino:W is NR₁₀, —(CO)(O)R₉, —N(R₁₀)SO₂—R₉, —O(CO)R₉, —(CO)NR₁₀, or—N(R₁₀)—CO—R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R₁₀ isH, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclicradical: Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆alkoxy: Z is C₂₋₈ heterocyclic radical with at least one basic nitrogenatom in the ring, optionally including in the ring up to 3 additionalheteroatoms or moieties independently selected from O, C═O, N, NH, NG,S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, orC₄₋₇ cycloalkenyl; and each of the above hydrocarbyl or heterocyclicgroups being optionally substituted with between 1 and 3 substituentsselected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical,phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the aboveheterocyclic groups may be attached to the rest of the molecule by acarbon atom or a heteroatom; or a pharmaceutically acceptable salt,amide, ester, or hydrate thereof.
 27. (canceled)
 28. (canceled)
 29. Amethod of claim 26, wherein said central nervous system disorder isselected from Alzheimer's disease, epilepsy, eating disorders, learningand memory disorders, migraine, sleep/wake disorders, allergic rhinitis,schizophrenia, mild cognitive impairment, and asthma.
 30. (canceled) 31.(canceled)
 32. (canceled)
 33. A method for treating a patient with anupper airway allergic response, said method comprising administering tothe patient a pharmaceutically-effective amount of a compound of formula(I):

wherein both dashed lines complete a carbon-carbon double bond, or bothare absent; R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl; each of R₅, R₆, R₇and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino; oneof R_(a), R_(b), R_(c), R_(d), and R_(e) is —WYZ and the others areindependently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;W is NR₁₀, —(CO)(O)R₉, —N(R₁₀)SO₂—R₉, —O(CO)R_(g), —(CO)NR₁₀, or—N(R₁₀)—CO—R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R₁₀ isH, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclicradical; Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆alkoxy; Z is C₂₋₈ heterocyclic radical with at least one basic nitrogenatom in the ring, optionally including in the ring up to 3 additionalheteroatoms or moieties independently selected from O, C═O, N, NH, NG,S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅;and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, orC₄₋₇ cycloalkenyl; and each of the above hydrocarbyl or heterocyclicgroups being optionally substituted with between 1 and 3 substituentsselected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical,phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the aboveheterocyclic groups may be attached to the rest of the molecule by acarbon atom or a heteroatom; or a pharmaceutically acceptable salt,amide, ester, or hydrate thereof.
 34. (canceled)
 35. (canceled)
 36. Acompound of claim 2 selected fromN-[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-2-pyrrolidin-1-yl-acetamide;2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine;2-[4-[3-(Piperidinyl)]propanamidophenyl]-8-methylimidazo[1,2-a]pyridine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amineand 3-Piperidin-1-yl-propane-1-sulfonic acid[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide.
 37. Apharmaceutical composition of claim 20 wherein said compound has aformula selected fromN-[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-2-pyrrolidin-1-yl-acetamide;2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine;2-[4-[3-(Piperidinyl)]propanamidophenyl]-8-methylimidazo[1,2-a]pyridine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amineand 3-Piperidin-1-yl-propane-1-sulfonic acid[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide.
 38. A method ofclaim 23 wherein said compound is selected fromN-[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-2-pyrrolidin-1-yl-acetamide;2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine;2-[4-[3-(Piperidinyl)]propanamidophenyl]-8-methylimidazo[1,2-a]pyridine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amineand 3-Piperidin-1-yl-propane-1-sulfonic acid[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide.
 39. A method ofclaim 26 wherein said compound is selected fromN-[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-2-pyrrolidin-1-yl-acetamide;2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine;2-[4-[3-(Piperidinyl)]propanamidophenyl]-8-methylimidazo[1,2-a]pyridine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amineand 3-Piperidin-1-yl-propane-1-sulfonic acid[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide.
 40. A method ofclaim 33 wherein said compound is selected fromN-[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-2-pyrrolidin-1-yl-acetamide;2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine;2-[4-[3-(Piperidinyl)]propanamidophenyl]-8-methylimidazo[1,2-a]pyridine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine;[4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amineand 3-Piperidin-1-yl-propane-1-sulfonic acid[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-amide.